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A b s t r a c t 
Estrogen fulfills a variety of physiological roles 
through its nuclear receptors, estrogen receptors (ERs). 
The action of ERs is modulated and mediated by diverse 
interacting cofactors. The initial aim of this thesis 
work was to identify ligand-, subtype- and/or cell type-
specific ER-interacting proteins. 
I identified a number of nuclear extract-derived 
proteins that interact with immobilized ER ligand binding 
domains (LBDs) in a 17(3-estradiol (E2)-dependent manner. 
The most prominent of these are components of the thyroid 
hormone receptor associated protein (TRAP)/Mediator 
coactivator complex, which interacts with ERa and ER(3 
both in unfractionated nuclear extracts and in purified 
form equally efficiently. Although some of other 
interacting proteins displayed subtype specificity, the 
main focus of the work was to characterize the function 
of TRAP/Mediator in ER-dependent transcription for both 
ERa and ER(3. 
Studies with extracts from TRAP220-/- mouse embryo 
fibroblasts (MEFs) revealed that the interactions between 
TRAP and ERs are dependent on TRAP22 0, a TRAP/Mediator 
subunit previously shown to interact with ER and other 
nuclear receptors in a ligand-dependent manner. The 
physiological relevance of the in vitro interaction was 
further documented by the isolation of an ERa-
TRAP/Mediator complex from HeLa cells expressing an 
epitope-tagged ERa lacking AB domain (f:ERa,AAB). Most 
importantly, the complete TRAP/Mediator complex was shown 
to directly enhance ER function in a highly purified cell 
free transcription system. 
I further examined the roles for TRAP2 2 0 NR box in 
ER-TRAP/Mediator interaction. Both NR boxes were found to 
be important for ER-TRAP/Mediator interaction. Transient 
transfection assays with TRAP220-/- MEFs revealed that 
the absence of TRAP220 or mutations in either or both NR 
boxes attenuated modestly ER dependent transcription in 
TRAP220-/- MEFs. This indicated that TRAP220 and its NR 
boxes are required for the optimal transcrictipationl 
activity of ER. However, the observation of the 
significant E2 responses in TRAP220-/- MEFs suggested the 
existence of alternative pathways for E2 responses 
different from TRA/Mediator or the absence of natural 
constraints that impose a requirement for TRAP220 to 
overcome. Similarly, cell-free transcription assays also 
showed modest defect in function of TRAP/Mediator for ER 
dependent transcription when TRAP/Mediator contains 
TRAP2 2 0 NR mutants. 
Chapter 1 
Introduction 
1.1. Estrogen Receptor 
The transduction of extracellular signals into 
intracellular responses is a vital and fundamental 
process of all living organisms. It is the means by which 
communication between the genetic attributes of an 
organism and surrounding nature takes place. Through this 
system, the living organism can achieve active adaptation 
to their surroundings resulting in long-term evolutionary 
process. One major system of communication that has 
evolved in higher eukaryotes is the endocrine system, 
which is coordinated by chemical messengers called 
hormones. Hormones influence the actions of many tissues 
and thus affect many processes including metabolism, 
growth, development, emotion, and behavior, in addition 
to contributing to homeostasis (Goodman, 1996a). The 
steroid hormone, estrogen, is considered a female sex 
steroid hormone because it is produced mainly from the 
ovary and controls the growth, differentiation, and 
function of female reproductive and accessory sex tissues 
(Goodman, 1996b). However, estrogen also influences male 
reproductive and accessory sex tissues (Luconi et al., 
2002). In addition to the reproductive tissues, non-
reproductive tissues are also targets of estrogen. These 
include skin, hair, bone, liver, pituitary, hypothalamus, 
cardiovascular system and behavioral centers in the brain 
(Farhat et al., 1996; Oursler, 1998; Toran-Allerand et 
al., 1999; Shupnik, 2002; McEwen, 2002). 
How does estrogen affect target tissues? Cells 
appear to have evolved two ways to respond to estrogen 
signals. These are termed the genomic and nongenomic 
responses. First, the classical genomic action of 
estrogen is mediated through nuclear receptors called 
estrogen receptors (ERs) of the target cells by 
regulating the expression of specific subsets of genes 
that lead to long-term physiological effects. On the 
other hand, the nongenomic action of estrogen involves 
mechanisms that are not necessarily mediated through 
changes in gene expression. Instead, they are thought to 
be mediated through interactions between estrogen and 
cellular membrane components such as lipids and/or 
possible membrane receptors (McEwen and Alves, 1999; 
Watson and Gametchu, 1999). There are reports suggesting 
the existence of novel membrane receptors that are 
distinct from ERs and their involvement in these effects 
(Luconi et al., 2001; Nadal et al., 2000). However, a 
number of studies have provided evidence that a 
subpopulation of ERs are present in the cellular membrane 
and play important roles in these rapid responses through 
intracellular signaling (Levin, 2002; Razandi et al., 
1999). This has suggested that ERs are the primary 
mediator of estrogen actions in both the genomic and the 
nongenomic pathways. 
1.1.1. ER is a member of nuclear hormone receptor family. 
Two subtypes of ER have been identified so far: the 
classical ERa (Green et al., 1986; Greene et al., 1986) 
and the recently discovered ER|3 (Kuiper et al., 1996). ERs 
are members of a large superfamily of nuclear receptors 
that function as ligand-regulated transcription 
activators. Like other nuclear receptors, ERs are modular 
proteins consisting of an amino-terminal region (A/B 
domain); a central DNA binding region (C domain); the 
carboxyl-terminal region (E domain) which is responsible 
for ligand-binding; the hinge region (domain D), which is 
located between the DNA and the ligand-binding domains; 
and the F domain, which is located at the extreme 
carboxyl terminus of the protein (reviewed in Gronemeyer, 
1991) . 
ERs contain two transcriptional activation functions 
(AFs), which are responsible for the expression of target 
genes; the ligand-independent, amino-terminal AF-1 and 
the ligand-inducible, carboxyl-terminal AF-2 (Tora et 
al., 1989). Both AF-1 and AF-2 are required to achieve 
maximal transcriptional activity of ER (Tzukerman et al., 
1994) through the cooperative action (Chen et al., 2000; 
Kobayashi et al., 2000) but can also function 
independently with certain cell type and promoter 
specificities (Tzukerman et al., 1994). In particular, 
AF-1 activity exhibits cell type and promoter context 
specificities (Berry et al., 1990; Tora et al., 1989), 
displays different potency in each ER subtype (Hall and 
McDonnell, 1999; Mclnerney et al., 1998) and is regulated 
via phosphorylation cascades (Kato et al., 1995) by 
facilitating recruitment of cofactors (Tremblay et al., 
1999). To date, a wide array of factors have been shown 
to interact with and enhance transcriptional activities 
of ERs. A large subset of these factors interact directly 
with the ER-LBD in a ligand and AF-2 dependent manner. As 
shown in three dimensional structures, upon ligand 
binding receptor undergoes conformational changes in the 
orientation of helix H12 within core AF-2 in order to 
allow cofactors to interact (reviewed in Pike et al., 
2000). 
1.1.2. Physiological roles of ER 
The recent development of estrogen receptor knockout 
(ERKO) mice has provided suitable models to study the 
physiological roles of ERs (Couse and Korach, 1999; 
Mueller and Korach, 2001; Nilsson and Gustafsson, 2002) 
As expected, the phenotypes exhibited in ERa knockout 
(referred as aERKO) mice due to estrogen insensitivity 
have demonstrated significant roles of ERa in the 
reproductive system and accessory sex tissues (Couse and 
Korach, 1999). These include functions: (1) in 
proliferation and differentiation of cells that are 
critical to the function of the adult female reproductive 
tract and mammary gland; (2) as an essential component in 
growth factor signaling in the uterus and mammary gland; 
(3) in negative regulation of gonadotropin gene 
transcription and LH levels in the hypothalamic-pituitary 
axis; (4) as a positive regulator of progesterone 
receptor (PR) expression in several tissues; (5) in the 
positive regulation of prolactin (PRL) synthesis and 
secretion from the pituitary; (6) as a promotional factor 
in oncogene-induced mammary neoplasia; and (7) as a 
crucial component in the differentiation and activation 
of several behaviors in both female and male (Couse and 
Korach, 1999). Genetic ablation of ERa also revealed 
essential roles for ERa in certain aspects of male 
reproduction, as reflected in phenotypes displayed in 
aERKO male mice such as production of abnormal sperm and 
the loss of intromission and ejaculatory response (Couse 
and Korach, 1999). Moreover, the phenotypes observed in 
aERKO mice have indicated more diverse roles of ERa in 
various nonreproductive tissues such as bone, brain and 
cardiovascular system (Mueller and Korach, 2001; Nilsson 
and Gustafsson, 2002). These aberrant phenotypes 
included: (1) growth arrest of longitudinal bones in both 
sexes as well as lower bone density in male mice, (2) 
increased aggression and infanticide in female mice as 
well as reduced aggression in male mice, (3) reduction of 
estradiol-induced angiogenesis and increase in serum 
apolipoprotein E, lower basal levels of vascular nitric 
oxide, increase in calcium channels and delayed cardiac 
depolarization (Couse and Korach, 1999). However, certain 
estrogen pathways in the aERKO female appear intact or 
unaffected, such as the ability of the uterus to 
successfully exhibit a progesterone-induced 
decidualization response, and the possible maintenance of 
an LH surge system in the hypothalamus including the 
proliferative and differentiative actions critical to the 
function of the adult female reproductive tract and 
mammary gland (Couse and Korach, 1999). 
Compared to aERKO mice, ER{3 knockout ((3ERK0) mice 
showed mostly normal phenotypes in both female and male 
mice, except for subfertility in female mice that may be 
due to infrequent and inefficient ovulation (Krege et 
al., 1998). This suggested that ER(3 is essential for 
normal ovulation efficiency but not for female or male 
sexual differentiation, fertility, lactation or certain 
other nonreproductive system (Krege et al., 1998). Loss 
of both receptors in the double ERKO (DERKO) mice leads 
to a striking sex reversal phenotype characterized by 
postnatal loss of oocytes and redifferentiation of the 
remaining somatic cells to Sertoli-like cells (Couse et 
al., 1999). This surprising ovarian phenotype of DERKO 
mice is distinct from that of the individual ERKO mice 
(Couse et al., 1999). This indicates cooperative actions 
of both receptors that are required for the maintenance 
of germ and somatic cells in the postnatal ovary (Couse 
et al., 1999). Analyses of the phenotypes of aERKO, (3ERK0 
and DERKO mice suggested specific contribution of each 
subtype of ERs as well as cooperative actions of both ERs 
in estrogen signaling (Couse et al., 1999). 
1.1.3. Actions of ER 
10 
What is the molecular basis of the above-mentioned 
physiological effects? What is the molecular mechanism of 
ER action that mediates estrogen signaling? This has been 
one of the most intensively studied subjects due to its 
clinical and pharmaceutical relevance. Long lasting 
clinical needs for novel hormone replacement therapies 
that retain the beneficial effects of estrogen, and at 
the same time do not possess the higher risk of breast 
cancer has driven the pharmaceutical industry to develop 
new Selective Estrogen Receptor Modulators (SERMs) that 
modulate ER in a tissue-selective manner. With respect to 
this, it is very important to understand the molecular 
mechanism of ER action underlying the behavior of SERMs. 
1.1.3.1. Genomic actions of ER 
The genomic actions of ERs have been well 
established. As ligand-modulated, DNA-binding 
transcription factors, ERs regulate expression of their 
target genes upon ligand binding. The process of genomic 
action of ER, thus, can be dissected into four major 
components, which together contribute to the modulation 
of ER function: ligands, DNA, ER and cellular factors. 
1) Ligands 
11 
Todate thousands of ligands for ERs have been 
synthesized. These compounds can be classified into 
agonist, partial agonist (partial antagonist) and pure 
antagonist depending on the ER response to these ligands. 
Early studies using protease digestion assays 
suggested that ligand binding induced a conformational 
rearrangement in the ligand binding domain (LBD) and 
hinted that the structure of ER-ligand complex might 
contribute to its functional specificity (McDonnell et 
al., 1995). Recent crystallographic analyses confirmed 
this idea by showing that different functional classes of 
ligands induce distinct conformations of ER in the 
orientation of helix H12 (reviewed in Pike et al., 2000). 
Agonist and antagonist bind at the same site within the 
core of the LBD but demonstrate different binding modes 
(Brzozowski et al., 1997; Pike et al., 1999; Shiau et 
al., 1998). In the case of agonists such as estradiol 
(E2) and diethylstilbestrol (DES), the ligand is 
completely encased within the ligand-binding pocket and 
helix H12 is aligned over the pocket (Brzozowski et al., 
1997; Shiau et al., 1998). This conformation allows 
peptides containing the short signature sequence motif 
(LXXLL motif where L is Leucine and X is any amino acid) 
known as the NR box to interact with the static region of 
12 
the coactivator recognition groove in AF-2 domain 
(Brzozowski et al., 1997; Shiau et al., 1998). The 
binding of the partial antagonists, tamoxifen (TAM) and 
raloxifene (RAL), however, is accompanied by major 
structural reorganization in the ternary structure in 
both ERs (Brzozowski et al., 1997; Pike et al., 1999; 
Shiau et al., 1998). The bulky side chain of the ligands 
protrudes out of the ligand-binding pocket. The resulting 
steric clashes (1) inhibit helix H12 from covering the 
ligand-binding pocket and instead, (2) force helix H12 to 
extend to the coactivator recognition groove, thereby 
imitating the interactions of ER with the NR box through 
its NR-box like sequence (LXXML where L is Leucine, X is 
any amino acid, and M is Methionine) (Shiau et al., 
1998). The structure of the ER|3 LBD bound to the ER(3 
partial agonist, genistein (GEN), reveals that ligand 
binding can stabilize yet another conformation of H12 
(Pike et al., 1999). In this complex, H12 is bound over 
the ligand-binding pocket in a position such that it 
occludes the coactivator recognition groove partially 
(Pike et al., 1999). However, the functional significance 
of this conformation of the LBD is unclear (Pike et al., 
1999). The side chain of ICI 164,384, a pure antagonist, 
binds directly to the coactivator binding cleft of ER(3, 
13 
causing physical blockade of H12 alignment (Pike et al., 
2001). Complete destabilization of H12 configuration and 
concomitant exposure of a large hydrophobic patch on the 
surface of ER-LBD is thought to be an account for rapid 
degradation of ICI-bound ER and such degradation is 
considered as a major mechanism of pure antagonism (Pike 
et al., 2001) . 
2) DNA 
As a template, DNA provides the genetic information 
for transcription. DNA also supplies its own regulatory 
information through gene-specific combinatorial 
arrangement of enhancer elements recruiting cognate 
sequence-specific DNA-binding transcription activators 
and distinct architecture of the core promoter. In this 
way, DNA is the key component to impose unique 
specificity to expression of a given gene. Consistent 
with this notion, DNA participates in important aspect(s) 
of regulation of ER function. 
Comparison of the promoter sequences of estrogen-
responsive genes led to the identification of the 
consensus estrogen response element (ERE), a palindrome 
of PuGGTCA motifs separated by 3 bp (Evans, 1988; Green 
and Chambon, 1988). ER interacts with DNA as dimers, with 
14 
one receptor interacting with each sequence motif 
(Gronemeyer and Meyer, 1991). The sequence-specific 
recognition of these elements is through the DNA binding 
domain (DBD) region of ER, which consists of two Cys4 
zinc fingers (Gronemeyer and Meyer, 1991). Mutation and 
crystallographic analyses revealed the molecular 
determinants dictating the sequence specificity of 
interactions between ERs and specific DNA elements 
(Danielsen et al., 1989; Mader et al., 1989; Umesono and 
Evans, 1989). 
The composition of the consensus sequence and the 
spatial organization of the motifs together with flanking 
sequences are important for the affinity and the 
specificity of ER binding. Although a few promoters of 
estrogen target genes contain EREs that match the 
consensus sequence (Xenopus Vitellogenin A2, human EFP, 
human EBAG9) (Ikeda et al., 2000; Inoue et al., 1993; 
Klein-Hitpass et al., 1986), most elements identified to 
date are not perfectly palindromic (reviewed in Klinge, 
2001). Deviations from the consensus in one half-site 
reduce ER-binding affinity in vitro (Nardulli et al., 
1996). It is interesting to note that the pS2 and the 
cathepsin D promoters, which both contain a T to C 
mutation in the PuGGTCA motif, were reported to function 
15 
poorly in endometrial carcinoma Ishikawa cells, but 
efficiently in breast carcinoma MCF7 cells (Miralles et 
al., 1994). Moreover, it has been suggested that the 
individual ERE sequences induce specific conformational 
changes in ER (Wood et al., 2001 and references therein). 
This ERE-induced allosteric modulation of ER conformation 
has been shown to affect the recruitment of specific 
coactivator proteins leading to differential gene 
expression from target genes containing divergent ERE 
sequences (Hall et al., 2002; Wood et al., 2001). These 
studies proposed that diversity of ERE sequences would 
provide mechanisms to determine the specificity of target 
gene activation by ERs. 
3) ER 
The surprising discovery that ER(3 is encoded by a 
gene different from ERa (Kuiper et al., 1996), has 
revealed the complexity of ER action and led to the 
reevaluation of the mechanism of ER function. ER(3 shows 
an overlapping but nonidentical tissue distribution 
compared to ERa (Kuiper et al. , 1997). ER(3 is 
predominantly expressed in testis, prostate, ovary, 
liver, and specific regions of the brain whereas ERa has 
been detected in several mouse tissues including the 
16 
mammary gland, uterus, ovary, liver, kidney, heart and 
testis (Couse and Korach, 1999). Some tissues, such as 
the thyroid gland, epididymis, bone and brain, express 
both ERs (Couse and Korach, 1999). However, very few, if 
any, of these tissues express both ERs in the same cell 
types implying that these receptors have distinct 
functional roles in mammals. For example, although rat 
ovary contains both ERs, ER(3 is located in the granulosa 
cells, whereas ERa is localized to the surrounding thecal 
cells (Hiroi et al., 1999; Sar and Welsch, 1999). 
In primary structure, human ER(3 displays some 
homology to ERa (reviewed in Pettersson and Gustafsson, 
2001). The maximal homology between ERa and ER(3 lies in 
their DBDs (96% identity) (Ogawa et al., 1998) indicating 
that both receptors share the same EREs (reviewed in 
Pettersson and Gustafsson, 2001). The LBD is also 
relatively conserved (53% identity) between these two 
receptors (Ogawa et al., 1998). Consistent with the 
primary structural homology, overall similarities in 
three dimensional structures of the LBD of both receptors 
were demonstrated in crystallographic studies (Pike et 
al., 1999; Shiau et al., 2002). Although ERa and ER|3 
exhibited similar binding affinities for most ligands 
(Kuiper et al., 1997), several new compounds have been 
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shown to bind preferentially to specific ER subtypes 
(Barkhem et al., 1998; Kuiper et al., 1998). This 
observation has led to the recent development of ER(3 
selective ligands (Katzenellenbogen et al., 2000; Sun et 
al., 1999). The N-terminal domains, namely the A/B 
domains of ERa and ER(3, share the least homology (30% 
identity)(Ogawa et al., 1998). Considering the 
observation that the A/B domain encompasses AF-1, whose 
activity acts in cell type- and promoter context-specific 
fashions (Berry et al., 1990), the poor homology between 
A/B domains of ERa and ER(3 implies that tissue-selective 
actions of SERMs could be partly but significantly due to 
functional distinction between two subtypes of ERs that 
has been attributed to the structural differences between 
the A/B domains. Consistent with this idea, ERa contains 
a strong AF-1 activity that results in the partial 
agonism of some antiestrogens such as TAM and RAL. In 
contrast, ER|3 shows, under the same conditions, 
negligible AF-1 activity and results in pure antagonism 
by TAM and RAL (Mclnerney et al., 1998) . Moreover, ERa 
and ER(3 shows opposite responses to the ligands on AP-1 
promoters (Paech et al., 1997). In the presence of 
estradiol, ERa activates transcription whereas ER(3 
represses transcription, but, in the presence of 
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antiestrogens, ER(3 is ten times more potent than ERa as 
a transcription activator (Paech et al., 1997). This 
difference also has been suggested to be a result of the 
structural difference between the A/B domains of ERa and 
ER(3 (Webb et al. , 1999). The studies reporting the 
existence of subtype-specific cofactors (Endoh et al., 
1999; Watanabe et al., 2001; Wu et al., 2001) provided 
evidence that these factors interact with ERa AF-1 and 
mediate its activity. Taken together, one can speculate 
that the different structural features the A/B domains of 
ERa and ER(3 contribute to the functional distinction 
between ERa and ER(3 through recruitment of different 
subset of cofactors. 
4) Cellular factors 
Lastly, the factors in the cellular environment 
contribute significantly to the regulation of ER 
function. As transcription factors, ERs communicate with 
a wide variety of factors such as gene-specific 
components of enhanceosomes, cofactors, chromatin 
remodeling factors, and general transcription factors 
(GTFs) (Beato and Sanchez-Pacheco, 1996). ERs also 
communicate with the components of other signal 
transduction pathways (Smith, 1998). 
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It is well established that the cellular milieu 
changes during the processes of proliferation, 
differentiation and/or development. At a given time point 
in a certain stage of differentiation and development, 
each cell has specific composition of factors depending 
on its tissue context. There are many types of tissue-
and/or stage-specific transcription factors that regulate 
cell function (Karin et al., 1990; Maniatis et al., 1987; 
Struhl, 1991). Additionally, the existence of tissue-
specific transcription cofactors has also been discovered 
(Luo et al., 1992; Luo and Roeder, 19 95). At least one 
component of general transcription machinery also 
displays tissue-dependent variation (Hansen et al., 
1997). Thus, the composition of available factors differs 
considerably depending on the cell type and stage of 
differentiation. Even in the same cell, each gene obtains 
its specificity in transcriptional regulation through 
unique combinatorial arrangements of the enhancer 
elements, in addition to the individual architecture of 
the core promoter. Therefore, ER-mediated transcriptional 
activation acquires cell-and/or promoter specificity via 
such specific cellular milieu and gene context. 
4-1) Transcription factors 
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It has been shown that ER functions indirectly 
through protein-protein interactions with other DNA-
binding transcription factors. The most studied example 
is the ER and activating protein-1 (AP-1) interaction. 
Ligand-activated ERa can interact with, and positively 
regulate, the collagenase gene promoter by associating 
with the AP-1 transcription factor complex within target 
cells (Webb et al., 1995). In this particular system, 
SERMs, such as TAM, manifest agonist activity. The ER-AP-
1 activity is particularly strong in endometrium-derived 
cell lines, where TAM is an agonist, whereas it is less 
active in cultured breast cancer cells, where TAM has 
antagonist activity (Webb et al., 1995). This study hints 
at a correlation between the ability to activate the 
ER—AP-1 complex and the ability of a cell to support the 
partial agonist activity of TAM. Moreover, the 
observation of the opposite responses of each subtype of 
ERs to E2 versus TAM on AP-1 promoters (Paech et al., 
1997) further corroborates the idea of the involvement of 
ER-AP-1 complex in tissue specific action of SERMs. 
Another well-known example is cooperative action of 
ER and Spl. In addition to the above-described ERE sites, 
GC boxes (GGGGCGGGG) or GT/CACCC boxes (GGTGTGGGG), which 
are binding sites for the transcription factor SP1, were 
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found to be associated with individual PuGGTCA motifs in 
regulatory regions of an increasingly large number of 
estrogen-responsive target genes (reviewed in Safe, 
2001). The importance of both the half-ERE and the Spl 
site for estrogen response have been indicated by studies 
using reporter plasmids containing the cathepsin D 
promoter or the RARa promoter. It was shown that 
mutations in either the Spl or the half-ERE part of 
composite motifs were no longer inducible by estrogen 
(Krishnan et al., 1994; Rishi et al., 1995). 
Cooperativity between ER and SPl was also observed with 
promoters containing palindromic EREs, such as that found 
in the vitellogenin Al and the rabbit uteroglobin 
promoter (Batistuzzo de Medeiros et al., 1997; Scholz et 
al., 1998). However, in some cases ERs may function 
cooperatively with Spl activity even without ERE. 
Deletion of the PuGGTCA motif in the promoter of the 
hsp27 gene did not affect its responsiveness to estrogen 
(Porter et al., 1997). Moreover, Spl sites in the 
promoters of the c-fos, bcl-2 and IGFBP4 genes were found 
to be sufficient for induction by estrogen (Safe, 2001). 
Interestingly, the effects of estrogen on Spl activity 
exhibited specificity depending on the cell line and the 
type of ER expressed. HeLa cells showed no activation of 
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Spl by estrogen when ERa was expressed, and a slight 
repression with ER(3(Saville et al., 2000). On the other 
hand, Spl sites were sufficient for stimulation by ERa 
but not ER(3 in MCF7 and MDA-MB-231 breast cancer cells 
(Saville et al., 2000). These studies suggested that 
ability to support cooperative actions of ER-Spl would be 
another possible way of cell type-specific actions of ER. 
There are other systems where these indirect 
transcriptional regulatory pathways have been shown to be 
important. For example, it has been shown in rodents that 
the retinoic acid receptor (RAR) promoter is upregulated 
both by estrogens and antiestrogens (Elgort et al., 
1996). Remarkably, even the pure antiestrogen ICI 182,780 
functions as an agonist on this promoter (Elgort et al., 
1996). Mutational analysis of the RAR promoter revealed 
that, in this system, ERa exerts its regulatory 
activities in an indirect manner through a pre-bound 
transcription factor (Elgort et al., 1996). The identity 
of this factor remains to be determined (Elgort et al., 
1996) . 
In a different system, antagonist-bound ER 
stimulated quinone reductase gene transcription through a 
previously defined electrophile-response element (Montano 
and Katzenellenbogen, 1997). In this system, ER(3 is a 
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more potent activator than ERa through stronger 
interactions with the human homologue of Xenopus gene 
which prevents mitotic catastrophe (hPMC2) (Montano et 
al., 1998; Montano et al., 2000). These findings 
indicated that ERs can contact the transcription 
apparatus in an indirect manner through several distinct 
types of protein—protein interactions meaning that there 
are at least two distinct mechanisms by which the ER can 
function as a transcriptional activator in target cells. 
There is some evidence, however, that ER, in some 
instances, can also function as a transcriptional 
repressor through these indirect regulatory pathways. In 
bone, for example, it has been shown that estrogens and 
antiestrogens effectively suppress production of 
interleukin 6 (IL-6), a cytokine required for 
osteoclastogenesis and osteoblastogenesis (Girasole et 
al., 1992; Jilka et al., 1992; Ray et al., 1994). The 
repression of IL-6 expression by ERs in osteoblasts and 
bone marrow stromal cells may explain in part the 
protective effects of circulating estrogen on bone 
density. Upon activation by ligand, the ER physically 
interacts with the p65 subunit of nuclear factor B (NF-
kB), thus blocking its ability to bind to target 
sequences located within the regulatory regions of the 
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IL-6 genes (Stein and Yang, 1995). In this process, only 
regions C to F of ERs are required for NF-kB repression 
suggesting that it does not involve ER binding to DNA. 
This regulatory paradigm might extend beyond NF-kB, as it 
has been shown that the ER can inhibit the 
transcriptional activity of CCAAT/enhancer binding 
protein (C/EBP) and GATA-1 in a similar way (Blobel et 
al., 1995; Stein and Yang, 1995). All together, these 
findings strongly support the physiological relevance of 
the inhibitory activity of ER. 
4-2) Cross-talk with signal transduction pathways 
Independent of estrogen signaling, other signal 
transduction pathways also regulate the transcriptional 
activity of ERs. Treatments with growth factors such as 
epidermal growth factor (EGF), insulin, insulin-like 
growth factor I (IGF-1), and transforming growth factor 
(TGF)-(3 can modulate transcriptional activity of ER 
through phosphorylation in the absence of estrogen 
(Smith, 1998). Early studies showed that EGF could mimic 
effects of estrogen in the mouse reproductive tracts and 
pretreatment of mice with the pure anti-estrogen greatly 
diminished the uterine response to EGF (Ignar-Trowbridge 
et al., 1992) suggesting the ER mediates this effect. The 
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lack of uterine response to EGFs in aERKO mice as 
described above (Couse and Korach, 1999) further 
supported the physiological relevance of EGF signal 
transdunction pathway in function of ERa. Typically, such 
cross-talk involves the direct phosphorylation of 
specific serine residues in AF-1 domains of both ERs by 
MAP Kinase (Kato et al., 1995; Tremblay et al., 1999). 
The net effect of these phosphorylation events is to 
potentiate AF-1 activity by facilitating recruitment of 
coactivators to the A/B domain in a ligand-and AF-2-
independent manner. In the case of ERa, the 
phosphorylation on Ser-118 of ERa by MAPK facilitates the 
recruitment of another cofactor, p6 8 (Endoh et al., 
1999). Additionally, the phosphorylation of ER(3 by MAPK 
resulted in a direct interaction between AF-1 and SRC-1, 
independent of ligand and the entire AF-2 sequences 
(Tremblay et al., 1999). Such phosphorylation cascades 
has been shown to be involved in the TAM-mediated agonism 
through modulation of AF-1 or its cofactors (Feng et al., 
2001) . 
The observation of E2-mediated downregulation and 
TAM-induced upregulation of HER-2/neu (a member of the 
EGFR family) synthesis (Newman et al., 2000) suggested 
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the existence of a cross-regulatory loop between estrogen 
signaling and other signal transduction pathways. 
4-3) Cofactors 
It is clear from the above-described studies that 
the regulatory mechanisms of ER function are diverse and 
complex. However, it appears that the regulatory 
information provided by distinct ligands, diverse EREs, 
different attributes of ER subtypes, differential 
cellular ability to support cooperative action with other 
transcription factors or signal transduction pathways are 
integrated to contribute to the recruitment of cofactors. 
This is the hypothesis from which my thesis work has 
started (see below). With this view, the dominant effect 
of ligands, agonism versus antagonism, depends on the 
potential of the ligand to either induce the correct 
conformation or disrupt the active conformation or, in 
other words, to respectively stimulate or prevent the 
correct binding of coactivators. 
In support of this idea, a recent report (Shang and 
Brown, 2002) provided compelling evidence that the 
differential recruitment of cofactors to nonclassical 
promoters (such as c-Myc) and/or modulation in cofactor 
expression (such as SRC-1) is the primary determinant for 
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agonism of TAM in either breast or endometrial cancer 
cells. This indicated that cell-type and promoter-
specific differences in cofactor expression and/or 
recruitment determine the cellular response to SERMs. 
1.1.3.2. Nongenomic actions of ER 
Estrogen can modulate protein function via 
nongenomic actions that are very rapid and cannot be 
accounted for by changes in transcription. Increasing 
number of studies have indicated that a subpopulation of 
ERs located in the cellular membrane play important roles 
in these rapid responses through intracellular signaling 
(Levin, 2002; Pappas et al., 1995; Razandi et al., 1999). 
For example, ERa has been shown to regulate MAP kinase 
activity in MCF-7 breast cancer cells through interaction 
with the SH2 domain of Src (Migliaccio et al., 1996) and 
lead to induction of cell proliferation (Castoria et al., 
1999). ER(3 acts by a similar mechanism in LNCaP prostate 
cancer cells (Migliaccio et al., 2000). Modulation of MAP 
kinase activity by estrogen has also been described in 
bone cells. Kousteni et al demonstrated that the 
estrogen-induced antiapoptotic effect is mediated by 
activation of Src/Shc/ERK signaling pathway via ER action 
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(Kousteni et al., 2001). Importantly, this study first 
provided evidence of the nongenomic effect of ER 
dissociated from transcriptional activity of ER by using 
synthetic ligands and peptide antagonists (Kousteni et 
al., 2001). Estrogen also regulates neuronal excitability 
(McEwen and Alves, 1999), intracellular calcium 
concentration, cyclic AMP synthesis and phosphoinositide 
turnover (reviewed in Kelly and Levin, 2001). Recently, 
ERa was shown to interact with the p8 5a regulatory 
subunit of the phosphatidylinositol-3-OH (PI3) kinase, 
resulting in increased enzymatic activity in vascular 
endothelial cells and leading to the activation of 
protein kinase B/Akt as well as endothelial nitric oxide 
synthase and the release of nitric oxide (Simoncini et 
al., 2000). This regulatory pathway may mediate the 
cardiovascular protective effects of estrogens, and 
appears to be specific to ERa and not ER(3 (Hisamoto et 
al., 2001). 
These mechanisms of estrogen action also contribute 
to gene expression via indirect pathways leading 
additional complexity in the regulation. It has been 
suggested that regulation of immediate early genes egr-1 
and c-fos by estrogen in MCF7 cells is mediated by their 
serum response elements via non-genomic activation of the 
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raf-MAPK signaling pathway (Duan et al., 2001; Pratt et 
al., 1998). The function of numerous transcription 
factors including AP-1 and ERs themselves is regulated by 
phosphorylation (Kato et al., 1995; Whitmarsh and Davis, 
1996). Therefore, the modulation of kinase activities by 
ERs is likely to contribute to fine-tuning of 
transcriptional regulation depending on the combination 
of transcription factors bound to a given promoter. In 
this way, non-genomic and genomic actions of estrogen may 
be intimately linked via cross-regulatory loops. 
The complexity of action mechanisms of ERs suggests 
that nature has engineered multiplicity into ER biology 
to fulfill different functions in different cells. 
1.2. ER-interacting proteins 
The actions of ER result from the interplay of all 
of factors that are involved. As described above, ER-
mediated transactivation is the process of the 
intercommunication between ER and the transcription 
machinery. Thus, the distinct characters of ligands and 
different attributes of ER subtypes are eventually 
integrated into the transcription machinery. Among the 
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main players in this process are the cofactors because 
they integrate differential signals and diversify the 
regulation to amplify specificity of transcription. A 
growing number of proteins have been identified in this 
category through its direct interaction with ER as well 
as other nuclear receptors in a ligand-dependent manner, 
1.2.1. SRC/pl60 family 
ER-associated protein (ERAP)140 and ERAP160 
(subsequently cloned as SRC-1 which is the first member 
of SRC/pl60 family, see below) were identified through 
GST pull down assays as the first ER interacting proteins 
(Halachmi et al., 1994). The potential role of ERAP160 in 
ER functions was suggested by the observation that it 
failed to interact with either antagonist-bound ER or 
with transcriptionally defective mutants of ER (Halachmi 
et al., 1994). SRC-1 was originally cloned through its 
interaction with LBD of PR by yeast two-hybrid analysis 
(Onate et al., 1995). The second member of this family 
is identified as TIF2/GRIPl/NcoA-2/SRC-2 (Hong et al., 
1997; Voegel et al., 1996). Concomitantly, 
AIBl/pCIP/ACTR/RAC3/TRAM-l/SRC-3 (Anzick et al., 1997; 
Chen et al., 1997; Li et al., 1997; Takeshita et al., 
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1997; Torchia et al., 1997) was discovered as the third 
member. These proteins share a conserved domain structure 
including the most conserved N-terminal basic helix-loop-
helix (bHLH) and Per/Arnt/Sim (PAS) domains that are 
implicated in protein-protein interactions (Aranda and 
Pascual, 2001). At the C-terminal end of the proteins 
reside two autonomous activation domains, a glutamine-
rich domain, and regions important for interaction with 
CBP (Torchia et al., 1997) and for the weak intrinsic HAT 
activity (Spencer et al., 1997). In the central part are 
located receptor interacting domains (RIDs) containing 
three LXXLL motifs that are essential for the 
interactions with nuclear receptors (Heery et al., 1997). 
These motifs have been implicated in determining the 
specificity of the interaction with nuclear receptors 
through differential requirement of each LXXLL motif in 
the interaction with specific receptors (Mclnerney et 
al., 1998). For instance, ERa preferentially interacted 
with the second motif and only one motif was sufficient 
to support stable interactions. The flanking sequences 
also contributed to the specificity of interaction and 
are important for SRC-1 function as well as interaction 
with ERa (Mclnerney et al. , 1998). 
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The functional significance of these proteins was 
well established by their ability to function as bona 
fide coactivators in vivo. For instance, SRC-1 showed a 
broad range of specificity in its function as a 
coactivator for several nuclear receptors as well as 
other transcription factors such as AP-1 and NF-kB. The 
important role of SRC-1 in ER functions was suggested by 
its stimulatory effect on the transcriptional activity of 
both ERa and ER(3 and this effect was inhibited by 
antiestrogens (Onate et al., 1995; Tremblay et al., 
1997). Moreover, the capability to reverse the ER-
mediated squelching effect on PR transactivation 
indicated that this protein is a limiting factor that is 
commonly recruited by both ER and PR. SRC-1 is also 
implicated in cooperative synergism between AF-1 and AF-2 
functions in ER through mediating functional interaction 
between AF-1 and AF-2 domains. Interestingly, TIF2 (a 
SRC-2) can stimulate ligand-dependent transcriptional 
activity only by ERa (Voegel et al., 1996) but not by ER(3 
(Bramlett et al., 2001). However, GRIP1, another SRC-2, 
was shown to function as a very strong coactivator for 
ER|3 on the collagenase promoter (Webb et al., 1998). SRC-
3 also showed functional preference in that it 
selectively enhanced the transcriptional activity of ERa 
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over that of ER(3 although it can interact with both ERa 
and ER(3 (Suen et al., 1998). These studies suggested that 
the specificity of ER functions is partly-this may be 
significant-dictated by the intrinsic functional features 
of SRC. This is consistent with the view that cofactors 
are major players in amplifying the specificity of ER 
function (reviewed in McKenna et al). Generation of 
knockout mice lacking SRCs has illuminated their 
physiological functions. The SRC-1 knockout mice were 
viable and fertile but exhibited growth reduction in 
estrogen target tissues (Xu et al., 1998). This included 
defects in uterine response to estradiol and mammary 
gland development in pregnant mice (Xu et al., 1998). 
Despite its broad functions as seen in cellular assays, 
the SRC-1 knockout mice showed relatively restricted 
defects. This, coupled with the observation of increase 
in TIF2 mRNA expression in SRC-1 knockout mice, indicates 
that certain compensatory mechanisms are involved in 
cofactor functions (Xu et al., 1998). Disruption of the 
SRC-3 gene in mice resulted in more dramatic phenotypes 
exhibiting growth retardation, delayed puberty, decreased 
reproductive function and blunted mammary gland 
development (Xu et al., 2000). Together with the original 
observation of the amplification of the SRC-3/AIB1 gene 
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in breast cancer (Anzick et al., 1997), the defects in 
the mammary gland development suggested a significant 
role of this cofactor in this tissue. 
1.2.2. P300/CBP 
P300 and CBP were originally isolated by their 
respective interaction with E1A (Eckner et al., 1994) and 
cAMP-regulated enhancer binding protein (CREB) (Kwok et 
al., 1994). They are now viewed as cointegrator proteins 
that function as common cofactors for diverse 
transcription factors to collate multiple signals into an 
integrated cellular response (Kamei et al., 1996). In 
this way, these proteins are involved in many important 
cellular processes including development, differentiation 
and oncogenesis (Goodman and Smolik, 2000). The 
involvement of p300/CBP in nuclear receptor functions has 
been suggested by gene deletion experiments, nuclear 
injection of blocking antibodies and transfection assays 
(Chakravarti et al., 1996; Chen and Okayama, 1987; 
Hanstein et al., 1996; Kamei et al., 1996; Kawasaki et 
al., 1998; Yao et al., 1996; Yao et al., 1998). Although 
direct interaction of p300/CBP with ERa through its RID 
has been clearly demonstrated in vivo and in vitro 
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(Hanstein et al., 1996), p300/CBP is now believed to be 
recruited to ERa via SRC-1 in the cell (Hanstein et al., 
1996; Torchia et al., 1997; Yao et al., 1996). With its 
potent intrinsic HAT activity (Ogryzko et al., 1996) 
p300/CBP has been believed to play a central role in ER 
dependent transcription by remodeling chromatin. This has 
been clearly demonstrated by the study with the cell free 
transcription assays using chromatin template (Kraus and 
Kadonaga, 1998). Similar to SRC-1, p300/CBP has been also 
shown to mediate synergism between AF-1 and AF-2 
(Kobayashi et al., 2000) through its interaction with AF-
1 domain of ERa and by facilitating phosphorylation-
dependent recruitment of SRC-1 to AF-1 domain of 
ER(3 (Tremblay and Giguere, 2001). 
1.2.3. AF-1 interacting proteins 
Recently, MMS19, the human homologue of the yeast 
DNA repair enzyme has been found to interact with the AF-
1 of ERa (Wu et al., 2001). Although it is not clear what 
the physiological relevance of this interaction is it 
might facilitate recruitment of RAC3 to the N-terminus of 
ERa through its interaction with PAS domain of SRC-3/RAC3 
(Wu et al., 2001) . 
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Surprisingly, an unusual RNA molecule called Steroid 
receptor RNA activator (SRA) has recently been described 
as an AF-1 specific cofactor for several steroid 
receptors including ERs (Lanz et al., 1999). SRA was 
found to be recruited to ERa via a subfamily of RNA-
binding DEAD-box proteins called p68/p72 which were 
identified as ERa AF-1 specific coactivators (Endoh et 
al., 1999; Watanabe et al., 2001). These proteins 
interact directly with AF-1 region of ERa but not of ER(3. 
This interaction was facilitated by phosphorylation by 
MAPK and led to potentiation of AF-1 activity of ERa 
(Endoh et al., 1999; Watanabe et al. , 2001). 
1.2.4. Other ER-interacting proteins 
There are many other factors that have been shown to 
interact with ERs and to stimulate ER dependent 
transcription including GTFs such as TBP (Sadovsky et 
al., 1995), TFIIB (Sabbah et al., 1998), and TFIIH (Chen 
et al., 2000b). Importantly, TFIIH has been shown to 
phosphorylate Ser-118 in a ligand-dependent manner 
through its interaction with ERa(Chen et al., 2000b). 
This study proposed the novel mechanism by which AF-1 
activity can be regulated by ligand and AF-2 activity. 
Along with several HATs other chromatin remodeling 
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factors such as SWI2/SNF2 (Ichinose et al., 1997) and 
BRG-1 (DiRenzo et al., 2000) have been implicated in ER 
dependent transcription. These proteins interact directly 
with LBD of ERa in a ligand-dependent manner (DiRenzo et 
al., 2000; Ichinose et al., 1997). This interaction 
absolutely required AF-2 domain (DiRenzo et al., 2000; 
Ichinose et al., 1997). In particular, BRG-1 is required 
for the function of SRC-1 and p300/CBP suggesting their 
cooperativity for ER function (DiRenzo et al., 2000). 
Another emerging group of proteins that are involved in 
nuclear receptor function by chromatin remodeling is 
histone methyl transferase (HMT) (Kraus and Wong, 2002). 
Coactivator-associated arginine methyltransferase 1 
(CARMl)(Chen et al., 2000a; Chen et al., 1999), protein 
arginine methyltransferasel (PRMT1) (Koh et al., 2001) 
and PRMT2 (Qi et al., 2002) have been shown to enhance ER 
dependent transcription synergistically with SRC-l/pl60 
through their direct interaction with the AD2 activation 
domain of SRC-l/pl60 but not directly with ER indicating 
their role as secondary factors. Another important factor 
for ER function is cyclin Dl indicating the tight link 
between ER function and the cell cycle. Cyclin Dl 
(without its CDK partner) was found to stimulate ER 
dependent transcription via direct interactions, which 
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were independent of ligand by recruiting SRC-1 (Zwijsen 
et al., 1998; Zwijsen et al., 1997). The physiological 
relevance was further highlighted by the recent 
demonstration that the interaction between ER and cyclin 
Dl was modulated by levels of cAMP in mammary epithelial 
cells (Lamb et al., 2000). 
Other cofactors such as TR-binding protein (TRBP) 
(Ko et al., 2000), transcription intermediary factor 1 
(TIF1) (Thenot et al., 1997), Coactivator independent of 
AF-2 function (CIA) (Sauve et al., 2001), E6-AP (Nawaz et 
al., 1999) and PPARgamma-coactivator-1 (PGC-1) 
(Tcherepanova et al., 2000) were found to enhance ER 
dependent transcription through their interaction with 
ERs. The physiological relevance of the interaction of 
these proteins with ERs remains to be studied. 
1.2.5. Corepressors 
Silencing mediator of RAR and TR (SMRT) (Horlein et 
al., 1995) and nuclear receptor corepressor (NcoR) (Chen 
and Evans, 1995) interact with the hinge region of RAR 
and TR in the absence of ligand and mediate basal 
repression of their respective target genes by recruiting 
many other factors such as histone deacetylases (HDACs) 
and Sin3 to form a repression complex (Jepsen and 
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Rosenfeld, 2002). This complex coordinates deacetylation 
of histones resulting in a condensation of chromatin and 
subsequent repression in transcription (Jepsen and 
Rosenfeld, 2002). Although the importance of these 
corepressors in nonsteroid hormone receptor function has 
been well known, their involvement in steroid receptor 
function was not yet fully demonstrated. However, ER has 
been found to interact with NcoR/SMRT and this 
interaction inhibits transcriptional activation in the 
presence of partial agonist such as TAM (Jackson et al., 
19 97; Smith et al., 1997). Furthermore, SRC-1 mediated 
TAM agonism was overcome by coexpression of SMRT 
indicating that these two proteins compete for access to 
partial agonist-bound receptor (Jepsen et al., 2000). 
This finding suggested that the expression level of these 
coregulators could be a determinant of tissue-selective 
agonism or antagonism of TAM (Jepsen et al., 2000). 
Further evidence for the involvement of NcoR/SMRT in ER 
function came from the discovery of SMRT/HDAC1 associated 
repressor protein (SHARP) by yeast two-hybrid analysis 
through the C-terminus of SMRT (Shi et al., 2001). This 
potent corepressor can attenuate SRA-induced ER 
transactivation by squelching SRA through the interaction 
of its RNA binding motifs with SRA and forming a complex 
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with several other corepressor proteins including HDACs 
(Shi et al., 2001). Interestingly, its mRNA level is 
induced in the breast cancer cell line MCF-7 upon 
treatment with E2 suggesting possible participation of 
SHARP in the feedback mechanism for the attenuation of 
the hormonal response (Shi et al., 2001). 
The effort to find a bona fide corepressor for ER 
has resulted in the cloning of REA (repressor of ER 
activity) (Delage-Mourroux et al., 2000). This protein 
represses the activity of both ERa and ER(3 through 
interaction with ERs in the presence of antagonists but 
does not affect transcription by other nuclear receptors, 
REA-dependent repression could overcome SRC-1 mediated 
stimulation of ER through its LXXLL motif. 
1.3. TRAP/Mediator 
The necessity for precise control of specific gene 
expression during complicated cellular processes creates 
numerous regulatory layers on the transcription process. 
This results in a great number of components that are 
involved in transcription. However, these protein 
components of the transcription machinery can be grouped 
into four categories by their functions: (1) sequence-
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specific DNA-binding transcription factors (Mitchell and 
Tjian, 1989); (2) chromatin remodeling factors including 
ATP-dependent remodeling factors and histone-modifying 
factors (Narlikar et al., 2002); (3) GTFs that are 
required for accurate transcription initiation from core 
promoters (Roeder, 1996); and (4) cofactors (Roeder, 
1998). Cofactors, used loosely, include chromatin 
remodeling factors. However, in this section, cofactors 
are more specifically defined as the factors that are not 
essential for basal transcription but that are necessary 
for the optimal induction or repression by sequence-
specific transcription factors without having intrinsic 
site-specific DNA binding activity and function beyond 
chromatin remodeling steps. The ultimate goal of the 
transcription activation can be represented as the 
facilitation of preinitiation complex (PIC) formation on 
the promoter (Keaveney and Struhl, 1998; Roeder, 1996). 
However, the access to the promoter is blocked by 
intrinsic structural features of chromatin. Therefore, 
the primary actions of transcription activators are (1) 
recruitment of a chromatin remodeling factors (Narlikar 
et al., 2002) and (2) induction of quantitative and 
qualitative changes of GTFs to promote PIC formation on 
the promoter (Roeder, 1996). Although many of 
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transcriptional activators can directly and physically 
interact with chromatin remodeling factors (Narlikar et 
al., 2002) and/or GTFs (Roeder, 1996), a large body of 
evidence suggested the major contribution of cofactors in 
effecting the communication among transcription 
activators, chromatin remodeling factors and/or GTFs 
through protein-protein interactions (Roeder, 1998) . 
1.3.1. Discovery of Mediator 
The concept of cofactors originally emerged from the 
"squelching effect" in which one activator could inhibit 
the stimulatory activity of a second activator in vivo 
(Gill and Ptashne, 1988; Triezenberg et al., 1988a; 
Triezenberg et al., 1988b). This notion was further 
corroborated by the requirement of additional activities 
from partially purified TFIID fractions to support 
activator function apart from what was then thought to be 
cloned TFIID, but is now known to be TATA-binding protein 
(TBP), the TATA binding component of TFIID (Hoffman et 
al., 1990; Pugh and Tjian, 1990). These observations 
pointed to a TBP-associated factor (TAF)-associated 
cofactor activity. 
The existence and function of novel cofactor 
activities, which are distinct from TAF-associated 
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activity, termed "mediator" in yeast (Flanagan et al., 
1991) and "upstream factor stimulatory activity" in 
metazoan system (Meisterernst et al., 1991) was first 
indicated by biochemical assays. These studies provided 
direct evidence that these activities are required to 
compensate the incapability of reconstituted 
transcription system with purified GTFs to achieve the 
optimal activity of sequence-specific activator-induced 
stimulation above the basal activity, which was seen in 
more crude system (Flanagan et al., 1991; Meisterernst et 
al., 1991). The attempts to further purify these 
activities to homogeneity were eventually succeeded in 
isolation of the multiprotein complexes that could indeed 
support activated-transcription in reconstituted 
transcription systems with purified GTFs (Kim et al., 
1994; Malik et al., 2000). 
Prior to these biochemical studies, yeast and 
metazoan Mediator (or Mediator-related) complexes were 
identified through independent studies. Early genetic 
analyses identified two groups of genes that are involved 
in transcriptional regulation (reviewed in Carlson, 1997) 
in vivo. The first includes suppressors of RNA polymerase 
B (II) (Srbs), and the other includes Galll, Rgrl, Rox3 
and Sin4 (reviewed in Carlson, 1997). The genetic screens 
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for suppressors of truncation mutation in the carboxyl 
terminal domain (CTD) of the largest subunit of pol II, 
rpbl, first identified nine genes: srb2 (Nonet and Young, 
1989), srb4-6 (Thompson et al., 1993), and srb7-ll 
(Hengartner et al., 1995; Liao et al., 1995). As they 
were originally identified the proteins involved in CTD 
function in vivo, SRB2, SRB4, SRB5 and SRB6 proteins, 
together with TBP, were found in a multisubunit complex 
that was associated with RNA polymerase II and bound 
specifically to recombinant CTD protein (Thompson et al., 
1993). Further characterization of this complex, termed 
holoenzyme, revealed that this complex could stimulate 
activated-transcription by GAL-VP16 (Koleske and Young, 
1994) and contained all nine SRB proteins and GAL11, 
together with TFIIB, TFIIF and TFIIH (Barberis et al., 
1995; Hengartner et al., 1995; Koleske and Young, 1994; 
Koleske and Young, 1995; Liao et al., 1995). 
The first human Mediator complex was discovered as 
TRAP (thyroid receptor-associated proteins) complex 
(Fondell et al., 1996). This complex was isolated through 
its intracellular association of the ligand-bound thyroid 
receptor (Fondell et al., 1996). TRAP complex was later 
found to be equivalent, in composition, function, and 
action mechanism (Ito et al., 1999), to SRB- and MED-
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containing Coactivator Complex (SMCC), which was isolated 
through independent efforts to identify a human 
holoenzyme complex corresponding to yeast holoenzyme (Gu 
et al., 1999). Other biochemical studies reported other 
human Mediator-related complexes including vitamin D 
receptor-interacting proteins (DRIP) (Rachez et al., 
1998), negative regulator of activated transcription 
(NAT) (Sun et al., 1998), activator-recruited complex 
(ARC) (Naar et al., 1999) and coactivator required for 
Spl (CRSP) (Ryu and Tjian, 1999). 
1.3.2. Structure of Mediator 
1.3.2.1. Subunit composition 
Yeast Mediator is composed of about twenty one 
subunits (Myers and Kornberg, 2 000; Boube et al., 2 002): 
above-mentioned nine Srbs (Srb2-ll); other genetically 
identified subunits including Gal11, Nutl, Rgrl, Rox3, 
Sin4, Med3/Hrsl/Pgdl, Med9/Cse2 and Medl0/Nut2 (Carlson, 
1997; Myers and Kornberg, 2000); and the last seven novel 
proteins (Med 1,2,4,6,7,8, and 11) that were 
biochemically identified by their presence in the 
SRB/Mediator complex (Myers et al., 1998). 
Metazoan Mediator complexes appeared to vary 
significantly in size and composition (Malik and Roeder, 
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2000). However, close comparison of their compositions 
and sizes reveals that they are essentially derived from 
an identical or a very similar cellular unit (Malik and 
Roeder, 2000). The largest human Mediator complex, 
TRAP/Mediator complex contains approximately twenty-five 
subunits (Gu et al., 1999; Malik et al., 2000; Baek et 
al., 2002). Among them, seventeen subunits are human 
orthologs of yeast Mediator components; TRAP2 4 0/SRB9, 
TRAP230/SRB8, TRAP220/MED1, TRAP170/RGR1, hSUR2/Galll, 
TPA-inducible gene (TIG)1/PC-associated Q-rich 
protein(PAQ)/ARC105/MED9, TRAP95/Sin4, TRAP80/SRB4, 
CDK8/hSRB10, p36/MED4, hMED7, Cyclin C/hSRBll, hMED6, 
TBP-related-factor-proximal protein (TRFP)/SRB2, 
TRAP25/Medll, hSRB7, hSOHl, hNUT2/MED10 (Malik and 
Roeder, 2000; Boube et al., 2002) and TRAP100, p37 are 
considered as species specific components. Additional 
subunits, p97, p93, p78, p22, pl2 remain to be 
characterized (Malik and Roeder, 2000). Any variation in 
composition and size of the metazoan Mediator complexes 
may be possibly in part due to different isolation 
procedures (Malik and Roeder, 2000). In addition, the 
intrinsic modular properties and/or different cellular 
states of the Mediator complexes might also lead to 
variable association of the components (Malik and Roeder, 
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2000; Myers and Kornberg, 2000), as reported in yeast 
Mediator (Kang et al., 2001). On the basis of 
compositional complexity and sizes, these various 
complexes can be classified into the smaller complexes 
including PC2, CRSP and the murine Mediator and the 
larger complexes including TRAP/Mediator, ARC, DRIP and 
NAT complexes (Malik and Roeder, 2000). In view of the 
notion that Mediator is a dynamic and modular 
organization, the smaller complexes could be considered 
as subcomplexes of the larger complexes as represented by 
PC2 and TRAP/Mediator (Malik et al., 2000) as well as 
CRSP and ARC-L (Naar et al., 1999; Ryu and Tjian, 1999). 
1.3.2.2. Three-dimensional structure 
As inferred from the comparison of their subunit 
composition, the recent studies by electron microscopy 
(EM) revealed considerable similarities between 
TRAP/Mediator and ARC-L as well as between CRSP and 
murine Mediator complex (Dotson et al., 2000; Taatjes et 
al., 2002). Additionally, comparison of murine Mediator 
and human TRAP complex hinted that structure of murine 
Mediator appeared to be a substructure of TRAP/Mediator 
(Dotson et al., 2000). Consistently, superposition of the 
structures of CRSP and ARC-L demonstrated that CRSP is 
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essentially a substructure of ARC-L (Taatjes et al., 
2002). More importantly, these structural analyses 
revealed significant structural features of Mediators. In 
the holoenzyme (Mediator and RNA polymerase II) state, 
three domains termed head, middle and tail of Mediator 
were extended and wrapped around a globular polymerase, 
in contrast to the more compact structure of its isolated 
state, suggesting that Mediator undergoes conformational 
changes in order to complex with polymerase (Asturias et 
al., 1999). Subsequent EM studies of CRSP complex showed 
activator-specific conformations of CRSP as distinct from 
its structure of the isolated form. Interestingly, 
certain activator i.e. VP16 can induce the conformation 
similar to CTD bound form (Naar et al., 2002; Taatjes et 
al., 2002). It was suggested that activator (VP16) could 
substitute for, but not compete with, a potential 
function of the CTD in activating transcription by 
inducing a CTD-bound conformation in the CRSP- In this 
way, activator can overcome CTD-dependent regulatory 
mechanisms that would otherwise moderate transcription 
initiation. Another possibility could be that activator 
binding induce such structural change in the conformation 
of Mediator to facilitate the formation of a holoenzyme 
complex which help basal machinery including RNA 
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polymerase II to form preinitiation complex at the 
promoter. 
1.3.3. Function of Mediator 
Mediator is now considered as a sensor, integrator, 
and processor (Kang et al., 2001). In this view, Mediator 
fulfills its primary function, as originally conjectured, 
by interconnecting diverse gene-specific regulatory 
proteins to the basal transcription machinery and 
providing more regulatory surfaces to transcription 
apparatus with its modular and dynamic organization. 
Three lines of evidence support this view. First of 
all, Mediator facilitates activated-transcription through 
direct interaction with a number of transcription 
activators including VP16 (Hengartner et al., 1995), Spl 
(Ryu and Tjian, 1999), adenovirus oncoprotein E1A (Boyer 
et al., 1999), and various nuclear receptors such as 
thyroid receptor (Fondell et al., 1996), vitamin D 
receptor (Rachez et al., 1998), estrogen receptor (ER) 
(Kang et al., 2002), peroxisome proliferator-activated 
receptor y2 (PPARy 2) (Ge et al., 2002) and hepatocyte 
nuclear factor 4 (HNF-4) (Malik et al., 2002). Secondly, 
the roles for Mediator in basal transcription have been 
supported by the following observations: (1) 
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copurification of yeast Mediator with polymerase II 
(Thompson et al., 1993; Kim et al., 1994; Koleske and 
Young, 1994), (2) association of TBP with SRB proteins 
(Koleseke et al., 1992; Thompson et al., 1993) (3) the 
requirement of Srb2 and Srb5 for stable PIC formation 
(Koleseke et al., 1992; Thompson et al., 1993), (4) 
complete shut-off of transcription from essentially the 
entire genome by the mutation in srb4, one of the core 
subunits of yeast Mediator (Holstege et al., 1998) and 
(5) TRAP/Mediator affected the basal transcription in 
TRAP/Mediator-depleted nuclear extract as well as 
activator-dependent transcription activity (Baek et al., 
2002; Mittler et al., 2001). Finally, a number of genetic 
and biochemical analyses have suggested that yeast 
Mediator is constituted with three functional modules 
termed the Galll, Med9/10, and Srb4 modules (Carlson, 
1997; Lee and Kim, 1998; Lee et al., 1999; Han et al., 
1999; Han et al., 2001; Kang et al., 2001; Boube et al., 
2002). This is consistent with the three-dimensional 
structure reconstructed by EM study, which also suggested 
dynamic properties of Mediator (Asturias et al., 1999; 
Dotson et al., 2000). The Galll module, constituting the 
tail region, (Dotson et al., 2000), includes Galll, Rgrl, 
Sin4, Med2, and Med3 (Lee and Kim, 1998; Lee et al., 
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1999). As Galll, Rgrl and Sin4 are originally identified 
by genetic analyses for transcriptional regulators 
(reviewed in Carlson, 1997), this module is thus proposed 
to function mainly in receiving signals from gene-
specific regulators (Lee et al., 1999; Han et al., 1999). 
In support of this idea, the proteins in this module were 
shown to be required for transcriptional activation and 
repression through direct interaction with activators and 
repressors (e.g., Gal4, Gcn4, Swi5, and Tupl) via 
distinct and/or common binding surfaces (Bhoite et al., 
2001; Han et al., 2001; Park et al., 2000, Han et al., 
1999; Lee et al., 1999; Myers et al., 1999). The middle 
domain of Mediator is the Med9/10 module together with 
the N-terminal portion of Rgrl (Dotson et al., 2000). 
This module is proposed to play a role in relaying 
regulatory signals (Han et al., 2001; Kang et al., 2001) 
through physical interactions among the Mediator subunits 
and basal transcription machinery (Kang et al., 2001). 
This module is composed of two stable substructures: the 
Med9 submodule containing Medl, -4, and —9, as indicated 
in genetic analyses, is thought to be involved in 
repression through physical interaction with Srbl0/ll, 
whereas the MedlO submodule comprising Srb7, Med7, MedlO, 
and possibly Nutl may transfer activating signals to the 
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basal transcription machinery (Han et al., 2001; Kang et 
al., 2001). The head domain, Srb4 module, includes Srb2, 
-4, -5, -6, Rox3, Med6, -8, and -11 (Kang et al., 2001). 
This module is thought to function as a signal processor 
that directly modulates activity of polymerase II through 
the physical interaction with polymerase II. This idea 
has emerged from the following observations: (1) the 
reconstituted SRB4 module interacts with basal 
transcription machinery and enhances basal transcription 
in a cell-free assay without major effect on activated 
transcription and CTD phosphorylation (Kang et al., 
2001); (2) srb2, -4, -5, and -6 genes were originally 
identified as suppressors of CTD truncation (Nonet and 
Young, 1989; Thompson et al., 1993); and (3) the apparent 
physical contacts between the head domain and Pol II was 
shown by EM studies (Asturias et al., 1999). Mediator 
under certain condition contains an accessory SrblO 
module composed of four Srbs, Srb8—11 (reviewed in 
Carlson, 1997) whose physical location within Mediator is 
yet unknown. This module is implicated in transcriptional 
repression via a modification of the polymerase II CTD 
prior to initiation (Hengartner et al., 1998) and through 
interactions with the Med9 submodule at least by a 
physical interaction of the SrblO with Medl and Med4 
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(Kang et al., 2001). Consistently, the depletion of the 
SrblO and Srbll pair by nutrient deprivation was 
associated with upregulation of a specific gene subset 
(Holstege et al., 1998). Moreover, the negative cofactor 
activity of TRAP/Mediator (Gu et al. 1999) was attributed 
to the enrichment of CDK8/SRB10 due to isolation 
procedures. This is because phosphorylation of cyclin H 
subunit of TFIIH by CDK8/SRB10 represses both the ability 
of TFIIH to activate transcription and its CTD kinase 
activity (Akoulitchev et al. , 2000). 
Regarding metazoan Mediator complex, its modular 
properties are not yet as clearly elucidated as yeast 
Mediator. However, emerging evidence indicated the 
modular properties of metazoan TRAP/Mediator. For 
example, as mentioned above, PC2 was found to be a 
submodule of TRAP/Mediator (Malik et al., 2000) and most 
subunits of CRSP are included in ARC complex (Naar et 
al., 1999). Moreover, the purified Mediator complex 
isolated from murine cells lacking Sur2 contains reduced 
amount of murine TRAP95 and murine TRAP100 (Stevens et 
al., 2002). Consistently, the TRAPlOO-deficient 
TRAP/Mediator complex derived from mouse embryonic 
fibroblasts of TRAP100 knockout mice also lacks TRAP95 
and SUR2, with a reduced amount of CDK8/hSRB10, 
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suggesting that these subunits may form a submodule (Ito 
et al., 2002). 
Another line of evidence suggesting the modular 
properties of metazoan Mediator is that each subunit (or 
group of subunits) of Mediator serves as a specific 
target for a distinct group of transcription factors. For 
example, TRAP220 is shown to be a main anchor for various 
nuclear receptors whereas TRAP80 serves as a specific 
target for p53 and VP16 (Ito et al., 1999). Human Sur2 is 
implicated as an integrator of the E1A and RAS signaling 
pathways (Boyer et al., 1999), while TRAP230 is involved 
in Wnt signaling (Zhang and Emmons, 2000). These studies 
also reinforce the idea that TRAP/Mediator, as a common 
and general cofactor, integrates multiple signals from 
diverse transcriptional activators to coordinate afferent 
signals from various signaling pathways. 
1.3.3.1. Functional mechanism of Mediator: 
The relationship with chromatin remodeling factors 
Transcriptional activation may be viewed as a two-
step process, an antirepression process to relieve the 
repression imposed by high order chromatin structure 
followed by PIC formation at the promoter (Roeder, 1998). 
The observation that TRAP/Mediator does not contain 
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intrinsic HAT activity and functions on naked DNA 
template in a purified system indicates that 
TRAP/Mediator mainly contributes to the PIC formation 
step (Roeder, 1998; Malik and Roeder, 2000). 
Additionally, the report of the competitive interaction 
of TRAP220 and TIF2 with TR or PPARy (Treuter et al. , 
1999) has suggested mutually exclusive recruitment of 
these proteins to transcription activators. Another 
important finding was the sequential interaction of 
cofactors with ligand-bound TR, TR-pl60/SRC-CBP/pCAF 
followed by TR-TRAP (Sharma et al., 2000). These have 
proposed the sequential multi-step model for 
transcription activation (Roeder, 1998; Ito and Roeder, 
2001 and references therein). In this model, 
transcription activation occurs in four steps: (1) 
activator binding to target sites within chromatin; (2) 
recruitment of chromatin remodeling factors including 
ATP-dependent nucleosome remodeling factors and HATs; (3) 
exchange of chromatin remodeling factors with 
TRAP/Mediator; (4) recruitment of RNA polymerase II and 
GTFs to form PIC. 
A recent report provided evidence for this model 
showing that TR, upon ligand binding, recruited HATs such 
as SRC-1, GRIP-1 and p300 ahead of the TRAP220 (Sharma 
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and Fondell, 2002). Prior to this study, however, the 
contrasting observation that TRAP220/PBP and AIB1 
concurrently occupied the cathepsin D promoter upon 
estrogen treatment had proposed the simultaneous and 
combinatorial recruitment model (Shang et al., 2000). The 
discrepancy between these studies might be attributed to 
the intrinsic differences between ER and TR (Sharma and 
Fondell, 2002). However, and more importantly, the 
observation of the requirement of pl60/GRIPl for 
TRAP220/PBP recruitment (Shang et al., 2000), actually 
provided evidence for the sequential action of these 
cofactors. Interestingly, Burakov et al suggested that 
TRAP220 subunit may have been recruited to the pS2 
promoter earlier than the rest of TRAP/Mediator complex 
(Burakov et al., 2002). Taken together, these results 
indicated that SRC/pl60 and TRAP220/PBP appeared to be 
recruited to the promoter simultaneously but the concrete 
recruitment of TRAP/Mediator complex might occur at the 
later step. 
1.3.3.2. Physiological roles of Mediator subunit 
In the multicellular organism, it is necessary to 
accommodate and incorporate diverse regulatory 
information needed to coordinate and specify the various 
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cell types. To fulfill this necessity, TRAP/Mediator, as 
a multiprotein complex, may provide a physical interface 
whereby subunits serve as specific targets for distinct 
regulatory signals. The genetic analyses in model 
eukaryotes have provided insights of the involvement of 
Mediator in the cellular mechanisms that allow the tight 
transcriptional regulation necessary for successful 
differentiation and/or development. 
Three genes encoding metazoan counterpart of MED6, 
SRB4, and SRB7 are essential for cell viability 
suggesting their general function in RNA polymerase II 
transcription (Tudor et al., 1999; Boube et al., 2000; 
Gim et al., 2001). In contrast to this, some of metazoan 
mediator subunits play more restricted but crucial roles 
in transcriptional regulation. For example, disruption of 
the murine TRAP100 has revealed that TRAP100 is not 
essential for cell viability per se, however, null mutant 
mice die at an early developmental stage with severe 
malformations (Ito et al., 2002). Similarly, although 
metazoan counterparts of Galll/Sur2, MED1/TRAP220, 
SRB8/TRAP230, and SRB9/TRAP240 are not required for cell 
viability or proliferation per se, these genes are 
necessary for the viability of the whole organism 
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(Stevens et al., 2002; Treisman, 2001; Boube et al., 
2000; Ito et al., 2000; Zhu et al., 2000). 
These subunits play their specific roles in 
transcriptional response to various signaling pathways, 
which are involved in cell differentiation through 
environment-directed cell fate decisions. The C. elegans 
Sur2/Galll, which functions downstream of the Surl MAP 
kinase (MAPK) pathway, is involved in a Ras-mediated 
signal transduction pathway (sur, suppressor of ras), 
which plays roles in the process of vulval induction 
(Singh and Han, 1995). Its null mutant showed pleiotropic 
phenotypes including partial larval lethality and sterile 
adults (Singh and Han, 1995). Consistently, human Sur2 
functionally interacts with MAPK-modified form of Elkl 
(Boyer et al., 1999). Furthermore, disruption of murine 
sur2 in embryonic stem cells leads to defective gene 
activation specifically by Elkl, but not by many other 
transcription factors (Stevens et al., 2002). These 
studies pointed to the conserved function of metazoan 
Galll, involving transcriptional regulation, 
particularly, in response to MAPK-dependent cell 
signaling. 
Srb8 and Srb9 represent another example of 
conservation of their specific roles in cell 
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differentiation in response to cell signaling pathways. 
In the slime mold, the protozoan counterpart of Srb9, 
namely AmiB, is specifically required to modify gene 
expression in response to nutrient depletion through its 
function in a cAMP-dependent signaling pathway (Kon et 
al., 2000). SRB8/TRAP230 and MED1/TRAP220 proteins in C. 
elegans were implicated to act in concert within a 
Mediator-related complex to block improper activity of 
the Wnt signaling pathway in V6 neuroblasts (Zhang and 
Emmons, 2001) and thus function in specification of V6 
cells via the pal-1-dependent genetic cascade as their 
genes, srb8/sopl and medl/sop3 were originally isolated 
as sop, suppressor of pal-1 (Zhang and Emmons, 2000, 
2001). In Drosophila, dSrb9/TRAP240 gene was originally 
identified as dose-sensitive modifiers of cell identity 
functions of the homeotic gene Sex combs reduced (Boube 
et al., 2000). Subsequent studies suggested that 
dSrb9/TRAP240 and dSrb8/TRAP230 function cooperatively to 
mediate developmental signals in early eye 
differentiation (Treisman, 2001). 
Another way to coordinate cellular functions is 
mediated via hormone signaling pathways. The TRAP220 is 
thought to be the pivotal subunit to mediate hormone 
action based on the observations of its ligand-dependent 
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interactions with various nuclear receptors (Yuan et al., 
1998), defective TR function in TRAP220-/- mice (Ito et 
al., 2000) and its essential functions in PPARy-
stimulated adipogenesis but not for MyoD-stimulated 
myogenesis (Ge et al., 2002). These studies provide 
strong evidence for the roles of TRAP220 in specific 
cellular processes. Altogether, the above-mentioned 
studies strongly supported the involvement of the 
Mediator complex in many important decisions controlling 
cell differentiation and development. 
1.3.4. Conservation throughout evolution 
The earlier observation that metazoan activators 
also can function in yeast hinted a high degree of 
functional conservation of the transcription apparatus 
over eukaryotic evolution (Flanagan et al., 1991). Recent 
studies supported not only functional (see above) but 
also structural conservation of Mediator. Electron 
microscopy data revealed the striking similarities in the 
overall appearance of isolated yeast and metazoan 
Mediator complexes (Asturias et al., 1999; Dotson et al., 
2000). In addition, all the known human Mediator subunits 
shared counterparts in fruit flies and worms indicating a 
high degree of structural conservation among metazoan 
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Mediator complexes (Kwon et al., 1999) (Park et al., 
2001) (Boube et al., 2000). Moreover, the extensive 
analyses of the newly available genomic sequences from 
eukaryotic species led to the identification of 12 
additional Mediator subunits conserved from yeast to 
human: Srb2/Trfp, Srb5/Med28b, Srb6/Surf5, Srb8/TRAP230, 
Srb9/TRAP240, Galll/Sur2, Sin4/TRAP95, Medl/TRAP220, 
Med4/TRAP36, Med8/ARC32, Med9/ARC105, and Medll/TRAP25 
(Boube et al., 2002). The conservation of overall subunit 
composition in Mediator from yeast to human suggests that 
the functional organization of yeast Mediator might be 
highly conserved in metazoan complexes (Boube et al., 
2002). Interestingly, a few mediator proteins are 
apparently present only in yeast and/or filamentous 
fungi, i.e., Nutl, Rox3, Med2, and —3 (Myers and 
Kornberg, 2000). Conversely, some human Mediator 
components appear specific to metazoans and/or plants, 
i.e., TRAP37, TRAP100, CRSP70, ARC42, and ARC92 (Boube et 
al., 2002). This, together with variations in the primary 
sequences of individual subunits might have been 
diversified during evolution to accommodate the species-
specific regulatory inputs emerging from novel gene-
specific transcription factors in eukaryotic evolution 
(Boube et al., 2002) . 
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Chapter 2 
Materials and Methods 
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A number of experimental procedures and materials 
have been repeatedly used throughout this work. They are 
usually described just once in the chapter where they 
were first used without being repeated in subsequent 
sections, unless significant modifications occurred. 
2.1. Materials and Methods for Chapter 3. 
Commercial reagents. 
17(3-estradiol (cat# E-2257) and N-lauroyl sarkosyne 
(Sarkosyl,cat# L-5777) were purchased from Sigma. Fetal 
bovine serum (cat# 16000044)was purchased from Gibco and 
Calf serum (cat# 12133-500M) was from JRH. 
Buffer BCn. 
20 mM Tris-HCl pH7.9 at 4°C, 20% (vol/vol) glycerol, 0.2 
mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM 
Dithiothreitol (DTT), supplemented with n mM of KCI. 
Plasmids. 
Plasmids encoding glutathione S-transferase (GST)-ERpLBD 
(243-530) were created by inserting the corresponding 
PCR-generated human ER(3 (hER(3) derivatives into the pGEX 
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vector (Pharmacia). hER(3 cDNA (a generous gift by Dr. 
Muramatsu) was used as templates for PCR reaction. 
GST-ERaLBD (302-595) was generously provided by Mitsuhiro 
Ito. 
Cell Lines. 
Immortalized mouse embryo fibroblasts (MEFs) from wild 
type and TRAP22 0_/" mice (Ito et al., 2000) by 
transformation with SV40 large T antigen were provided by 
Chao-Xing Yuan. HeLa derived cell line that stably 
expresses FLAG(f)-tagged Nut2 proteins (f:Nut2) (Malik et 
al., 2000) was used to purify TRAP/Mediator complex. 
Cell Culture. 
MEFs were maintained in Dulbeco's Modified Eagle's medium 
(DMEM) with 10% fetal bovine serum. HeLa cells were 
maintained in Joklik minimal essential medium with 10% 
calf serum and then transferred to DME-P04 medium 
containing 10% calf serum to achieve high density 
(107ml) . 
Extract Preparation. 
Nuclear extracts and S100 extracts were prepared as 
described previously (Dignam et al., 1983). 
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Immunoaffinity purification of FLAG-tagged protein-
assoiciated complex. 
Typically, one milliliter of nuclear extract prepared 
from the cell line was adjusted to 300 mM KCI with 0.05% 
(vol/vol) Nonidet P-40 (NP-40) and incubated with 2 0|xl of 
anti FLAG M2-agarose beads (Sigma), which had been 
preequilibrated with BC300-0.05% (vol/vol) NP40, at 4°C 
for 4-6 hours with gentle rotation. After 5 times of 
washing with BC300-0.1% (vol/vol) NP-40, the proteins 
were eluted by incubation of 20[xl of BC300-0.05% 
(vol/vol) NP-40 with 0.2 mg/ml of the FLAG peptides at 
4°C for 3 0 minutes. 
Bacterial Expression of GST fusion proteins. 
GST and GST fusion proteins were expressed and purified 
as described previously (Burakov et al., 2000). 
GST-Pull-Down Assays with Nuclear Extracts. 
GST pull-down assays were performed as described 
previously (Rachez et al., 1998). Before incubation with 
HeLa nuclear extract, all glutathione-Sepharose bead-
immobilized GST or GST-fusion proteins were normalized to 
equimolarity following quantitation by SDS-PAGE. 
Immobilized GST or GST-fusion proteins (20 u.g) were 
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preincubated for 1 hour at 4°C with ligand (1 uM E2)or 
carrier in binding buffer (20 mM N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES)-
KOH, pH 7.9, 20% (vol/vol) glycerol, 0.2 mM EDTA, 180 mM 
KCI, 1 mM DTT, 0.05% (vol/vol) NP-40, 0.5 mM PMSF) 
containing lmg/ml BSA. Immobilized proteins on beads were 
then incubated at 4°C for 6-14 hours with 4-10 mg of HeLa 
nuclear extracts adjusted to 180 mM KCI, plus 1 .uM E2 or 
carrier (ethanol). After 5 times of washing with 1 ml of 
washing buffer (20 mM HEPES-KOH, pH 7.9, 20% (vol/vol) 
glycerol, 0.2 mM EDTA, 180 mM KCI, 1 mM DTT, 0.1% 
(vol/vol) NP-40, 0.5 mM PMSF), bound proteins were eluted 
by incubating the beads with washing buffer containing 
0.2% (vol/vol) sarkosyl. The eluates were subjected to 4-
20% gradient SDS-PAGE, and then analyzed either by silver 
staining with Rapid Ag Stain Kit (ICN) or by western blot 
with ECL (Amersham) according to manufacturer's 
instructions. 
Preparation of proteins for Mass Spectral Analysis. 
For mass spectral analysis, eluates from GST-pull down 
with were subject to SDS-PAGE followed by Zinc staining 
(BioRad) according to manufacturer's instruction. The 
polypeptides were extracted from the gel and analyzed by 
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MS/MS by Dr. Wenzhu Zhang at Brian Chait's Lab. The MS/MS 
data were analyzed by Masscot. 
2.2. Materials and Methods for Chapter 4. 
Plasmids. 
GST-ERaAB (1-180) and GST-ER(3AB (1-153) were created by 
inserting the corresponding PCR-generated human ER(hER) 
derivatives into the pGEX vector (Pharmacia). hERa cDNA 
(purchased from ATCC) was used as template for PCR 
reaction. The plasmids for ER baculoviral expression were 
created by subcloning FLAG-tagged hERa(full-length 
cDNA) and hER(3( full-length cDNA) into pVL1392 vector 
(Invitrogen). 
4EREA53 was generously provided by Dr. Chengming Chiang 
(Wu et al., 1999) . 
Baculoviral Expression of Recombinant ER proteins. 
Recombinant FLAG-tagged ERs were expressed as described 
previously (Wu et al., 1999) with slight modifications. 
Briefly, 1 pg of each plasmid was incubated with 0.25 pg 
of Bac3000 linear DNA (Novagen), 1 jul of cationic 
liposome solution (Novagen), and 0.5 ml of Grace's 
medium. The mixture was vortexed vigorously, left at room 
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temperature for 15 min, and then added to a 60-mm plate 
containing ~2 x IO6 Sf9 cells. After incubation for 4 
hours, 1.5 ml of TNM-FH was added to the plate. 
Incubation was continued in a 2 7 °C humidified chamber 
for 5 days. The supernatant, collected after pelleting 
cells at 3,000 rpm for 5 min, was designated as the PO 
virus stock. 0.5 ml of PO was incubated with -4xl05 Sf9 
cells in a 60-mm plate containing 3 ml of TNM-FH. After 5 
days, the supernatant (PI virus, 0.5 ml) was used to 
infect 6xl06 Sf9 cells in a 150-mm plate containing 25 ml 
of TNM-FH. The supernatant (P2 virus, 5 ml), collected 
after 5 days of incubation, was used to infect 250 ml 
(~0.6xl06 cells/ml) of Sf9 cells in suspension. Fifty ml 
of the final P3 virus stock, collected after a 5-day 
incubation, was then used to infect 500 ml (1 xlO6 
cells/ml) of Sf9 cells for protein production, which was 
conducted for 48 to 60 hours. In the interim, estradiol, 
if included, was added to the medium at a final 
concentration of 10 nM, 16 h before harvest. 
Purification of Recombinant ER proteins. 
To purify FLAG-tagged ER, cells were collected by 
centrifugation at 3000 rpm for 10 minutes in a JS 4.2 
rotor at 4 °C. After washing with cold phosphate-buffered 
69 
saline (PBS) nuclear extract was prepared as described 
previously (Dignam et al., 1983) with modifications. 
Instead of adding low salt buffer and high salt buffer 
separately, nuclear extract buffer (20 mM Hepes, pH 7.9, 
25% (vol/vol) glycerol, 0.2 mM EDTA, 420 mM NaCl, 1 mM 
DTT, 0.05% (vol/vol) NP-40, 0.5 mM PMSF, ImM Benzamide, 
ImM Na3V04, 1\M E2) was used to extract nuclear proteins. 
14 ml of the nuclear extract was incubated with 0.1 ml of 
anti-FLAG M2-agarose (Sigma) at 4 °C for 4 to 6 hours. 
The immobilized proteins were then washed 5 times with 10 
ml of BC600-0.1% (vol/vol) NP-40 followed by washing with 
BC100-0.05% (vol/vol) NP-40 and finally eluted with 
elution buffer (BC100 for the first elution, and BC300 
for the next elution) containing 0.2 mg/ml FLAG peptide 
and 0.05% (vol/vol) NP-40. 
Cell lines. 
HeLa-derived cell lines expressing FLAG(f)-tagged Thyroid 
hormone receptor (f:TR) (Fondell et al., 1996), 
f:CDK8/SRBlO (Gu et al., 1999), f:TRAP220AB(1-670) 
(C.X.Y. and R.G.R, unpublished) were used to purify the 
corresponding TRAP/Mediator complexes containing these 
FLAG-tagged proteins. Chao-Xing Yuan established a HeLa-
derived cell line (C8) that stably expresses f:hERaAAB 
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(160-595), which was used to purify the 
hERaAAB-associated proteins. 
Antibodies and Western Blot Analysis. 
Antibodies against TRAP/Mediator subunits were described 
previously (Yuan et al., 1998) (Ito et al., 1999) (Malik 
et al., 2000). Western blot analyses involved standard 
procedures with an enhanced chemiluminescence detection 
kit (Amersham) according to manufacturer's instruction. 
GST-pull down assays with purified proteins. 
GST pull-down assays were performed as described in the 
previous section. Instead of nuclear extracts the 
purified complex supplemented with 2 mg/ml of BSA was 
incubated with immobilized proteins on beads at 4°C for 
6-14 hours under the same binding condition then 
processed and analyzed as described previously. 
Immunoaffinity pull down assays. 
All anti FLAG M2-agarose bead-immobilized f:ER proteins 
were normalized to equimolarity following quantitation by 
SDS-PAGE. Immobilized f:ER proteins (10 .ug) on beads as 
well as the same volume of empty M2-agarose beads were 
preincubated for 1 hour at 4°C with ligand (1 uM E2)or 
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carrier in binding buffer (20 mM HEPES-KOH, pH 7.9, 20% 
(vol/vol) glycerol, 0.2 mM EDTA, 180 mM KCI, 1 mM DTT, 
0.05% (vol/vol) NP-40, 0.5 mM PMSF) containing lmg/ml 
BSA. The beads were then incubated at 4°C for 6-14 hours 
with 8-10 mg of HeLa nuclear extracts adjusted to 180 mM 
KCI, plus 1 .uM E2 or carrier. After 5 washes with 1 ml of 
washing buffer (20 mM HEPES-KOH, pH 7.9, 20% (vol/vol) 
glycerol, 0.2 mM EDTA, 180 mM KCI, 1 mM DTT, 0.1% 
(vol/vol) NP-40, 0.5 mM PMSF) bound proteins were eluted 
by incubating the beads with washing buffer containing 
0.2 mg/ml of FLAG peptides. The eluates were subjected to 
4-20% gradient SDS-PAGE, and then analyzed by western 
blot with ECL (Amersham) according to manufacturer's 
instructions. 
In vitro translation of ER. 
35S-labelled ER(3 was expressed by TNT T7 coupled 
reticulocyte lysate systems (Promega cat#L4610) according 
to manufacturer's instructions. 
Interactions of purified TRAP/Mediator and full-length 
ER. 
TRAP/Mediator complex purified from the cell line 
expressing f:TRAP220AB was immobilized on anti FLAG M2-
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agarose beads. Translation mixture containing the 
expressed full-length ER and mock translation mixture 
were preincubated for 1 hour at 4°C with ligand (1 u.M 
E2)or carrier in binding buffer (20 mM HEPES-KOH, pH 7.9, 
20% (vol/vol) glycerol, 0.2 mM EDTA, 180 mM KCI, 1 mM 
DTT, 0.05% (vol/vol) NP-40, 0.5 mM PMSF). Immobilized 
TRAP/Mediator on beads as well as the same volume of 
control empty M2-agarose beads were then incubated with 
each translation mixture at 4°C for 6-14 hours in the 
binding buffer with 1 mg/ml of BSA plus 1 ,uM E2 or 
carrier. After washing 5 times with 1 ml of washing 
buffer (20 mM HEPES-KOH, pH 7.9, 20% (vol/vol) glycerol, 
0.2 mM EDTA, 180 mM KCI, 1 mM DTT, 0.1% (vol/vol) NP-40, 
0.5 mM PMSF) bound proteins were eluted by incubating the 
beads with washing buffer containing 0.2 mg/ml of FLAG 
peptides. The eluates were subjected to 4-20% gradient 
SDS-PAGE, and then analyzed by western blot with ECL 
(Amersham) according to manufacturer's instructions. 
In Vitro Transcription Assays. 
In vitro transcription assays were done by Mohamed 
Guermah. Reactions contained TFIID, TFIIB, TFIIE, TFIIF, 
TFIIH, RNA polymerase II, PC4 and other components 
(TRAP/Mediator and ERs) as indicated. All factors were 
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either recombinant or natural affinity-purified 
components that were isolated and utilized under 
previously described conditions (Guermah et al., 2001). 
2.3. Materials and Methods for Chapter 5. 
Plasmids 
F:GAL4-ER LBDs were created by exchanging p53 of f:GAL4-
p53 (Thut et al., 1995) with ER LBDs of GST-ER LBDs 
followed by subcloning into FASTBAC vector (Gibco). G5A53 
described previously (Kundu et al., 2000) was kindly 
provided by Woojin An. In transient transfection assays 
the reporter construct was 3ERE-Xp-Luciferase construct 
provide by Chao-Xing Yuan contained 3 ERE sites and 
adenovirus major late core promoter in pGL2 vector 
(Promega). pHEGO-Hyg (ATCC ) and pCXN2-ER(3 from Dr. 
Muramatsu were used for mammalian expression of ERa and 
ER(3 respectively. All TRAP220 constructs were generously 
provided by Chao-Xing Yuan. 
Cell lines. 
HeLa-derived cell lines expressing FLAG(f)-tagged 
TRAP220AB (1-670),f:TRAP220a,f:TRAP220b.f:TRAP220ab 
(C.X.Y. and R.G.R, unpublished) were used to purify the 
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corresponding TRAP/Mediator complexes containing these 
FLAG-tagged proteins. TRAP220AB contains N-terminal part 
of wild type TRAP220 (1-670). TRAP220a is the same N-
terminal fragment with point mutation (LXXLL-LXXAA) in 
the first LXXLL motif, TRAP220b is the one with point 
mutation (LXXLL-LXXAA) in the second LXXLL motif and 
TRAP22 0ab is the one with double mutation in both LXXLL 
motives. 
TRAP/Mediator-depleted Nuclear Extracts. 
TRAP/Mediator-depleted nuclear extracts were provided by 
Hwa Jin Baek and Xiaoting Zhang. Hwa Jin Baek used 
antibody against 25-1 for immunodepletion of 
TRAP/Mediator from HeLa nuclear extract as described 
previously (Baek et al., 2002) and Xiaoting Zhang used 
antibody against TRAP220 (Xiaoting Zhang and RGR, 
unpublished results) for depletion of TRAP/Mediator from 
Namalwa nuclear extract. 
Transient transfection assays. 
Transfection was carried out using FuGENE 6 reagent 
(Roche) according to manufacturer's instructions with 
slight modification. MEF cells were plated in 24-well 
plates (5xl04 cells/well) in phenol red-free DMEM with 
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10% charcoal-stripped fetal calf serum. The following day 
transfection was carried out using FuGENE 6 reagent 
(Roche) with 0.35 yiq of DNA comprising 1-5 ng of estrogen 
receptor expression vector, 250 ng of luciferase reporter 
vector, and 100 ng of TRAP220 or empty vector and pRL-CMV 
for internal control. After incubation at 37 °C for 5 
hours cells were treated with either E2 or carrier. After 
another 36 hours cells were harvested and assayed for 
luciferase activity by Dual Luciferase Assay system 
(Promega) according to manufacturer's instruction. 
Baculoviral Expression of GAL4-ER LBDs. 
GAL4-ER LBDs were expressed and purified as described in 
the materials and methods for chapter 4. 
Purification of General Transcription Factors. 
TFIIB (Ge et al., 1996), TFIIE (Ohkuma et al., 1995), 
TFIIF (Wang et al., 1994) and PC4 (Ge et al., 1996) were 
expressed and purified as described previously . TFIID 
was purified from the cell line expressing f:TBP (3-10) 
(Chiang et al., 1993) as described previously (Ge et al., 
1996). TFIIH and RNA polymerase II were immunoaffinity 
purified from the cell lines expressing f:ERCC3 (C3a) and 
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f:RPB9(B9b) respectively (unpublished materials by Chao-
Xing Yuan). 
In Vitro Transcription Assays with nuclear extract. 
In vitro transcription assays with nuclear extracts were 
carried out essentially as described previously (Dignam 
et al., 1983). Transcription reactions were performed in 
a final volume of 25 u.1. Transcription reaction contained 
the indicated factors (such as GAL4 fusion proteins and 
TRAP/Mediator complex), 5 fil (-50 [ig of total proteins) 
of HeLa nuclear extract, 35 ng of each supercoiled 
plasmid DNA template, 20 mM HEPES-KOH, pH7.9, 12% 
(vol/vol) glycerol, 60 mM KCI, 4 mM MgCl2, 0.5 mg/ml BSA, 
8 mM DTT, 0.5 mM ATP and CTP, 0.12 5 mM UTP, 0.1 mM 3'-0-
Met-GTP, 10 .uCi 32P UTP, 40 U of recombinant RNasin 
(Promega), Activator and DNA templates were preincubated 
at room temperature for 10 to 15 minutes followed by 
addition of nuclear extracts and another 20 minute-
incubation on ice. Transcription was initiated by 
addition of NTPs and processed and analyzed as described. 
In Vitro Transcription Assays reconstituted system with 
purified factors. 
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In vitro transcription assays with reconstituted system 
with purified factors were carried out essentially as 
described previously (Malik et al., 2000). Transcription 
reaction included the same components as described above 
except 5 ng of TFIIB, 7.5 ng of TFIIE, 10 ng of TFIIF, 75 
ng of PC4, TFIID equivalent to 2 ng of TBP, 2 0 ng of 
TFIIH, 50 ng of RNA polymerase II instead of nuclear 
extracts and other components (TRAP/Mediator and ERs) as 
indicated. Activator and DNA templates were preincubated 
at room temperature for 10 to 15 minutes followed by 
addition of general transcription factors and another 2 0 
minute-incubation on ice. Transcription was initiated by 
addition of NTPs and processed and analyzed as described. 
2.4. Materials and Methods for Chapter 6. 
Antibodies and Western Blot Analysis. 
Antibody against EDD/hHYD was kindly provided Dr. Watts 
(Callaghan et al., 1998). Western blot analyses involved 
standard procedures with an enhanced chemiluminescence 
detection kit (Amersham) according to manufacturer's 
instruction. 
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In vitro translation of EDD/hHYD derivatives 
35S-labelled various EDD/hHYD derivatives from the 
constructs provided by Dr.Watts (Callaghan et al., 1998) 
were expressed by TNT T7 coupled reticulocyte lysate 
systems (Promega cat#L4610) according to manufacturer's 
instructions. 
Transient transfection assays. 
Transfection was carried out using FuGENE 6 reagent 
(Roche) according to manufacturer's instructions with 
slight modification. CV1 and Ishikawa cells were plated 
in 24-well plates (5xl04 cells/well) in phenol red-free 
DMEM with 10% charcoal-stripped fetal calf serum. At the 
following day, transfection was carried out using FuGENE 
6 reagent (Roche) with 0.75 pq of DNA comprising 1-5 ng 
of estrogen receptor expression vector, 250 ng of 
luciferase reporter vector, and indicated amount of the 
plasmids containing EDD/hHYD full-lenth or empty vector 
and pRL-CMV for internal control. After incubation at 37 
°C for 5 hours cells were treated with either E2 or 
carrier. After another 36 hours cells were harvested and 
assayed for luciferase activity by Dual Luciferase Assay 
system (Promega) according to manufacturer's instruction. 
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Chapter 3 
Identification of ER-interacting Proteins 
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3.1. Introduction 
Due to the clinical and physiological importance of 
estrogen and SERMs, the molecular mechanism of ER-
mediated gene expression has received increased attention 
and becomes one of the most studied subjects. As a 
result, many diverse molecular mechanisms of ER-mediated 
gene expression have been suggested and numerous factors 
have been shown to be involved in those processes (see 
above). In 1994, an apparent involvement of cofactors in 
ER function emerged from the discovery of ERAPs (Halachmi 
et al., 1994). In 1996, the striking discovery of the 
second ER, which is encoded by a different gene and 
exhibits dissimilarity with ERa in many aspects including 
its primary structure (Kuiper et al., 1996), revealed 
another layer of complexity of ER action and led to a 
reevaluation of ER action in estrogen signaling. 
Although the mechanisms that regulate ER functions 
appear to be complex and diverse, they eventually could 
be integrated into one that modulates the communication 
properties of ERs. Given that ERs, as components of huge 
multiprotein transcription machinery, communicate with 
other factors via direct and/or indirect interactions, 
the actions of ER is the result of the interplay by all 
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the factors that are involved. The primary factors that 
mediate and modulate this communication process, by 
integrating the different signals and diversifying the 
regulatory controls, are thought to be cofactors (see 
above). In support of this notion, the first crystal 
structures of ERa LBD complexed with E2 and RAL 
demonstrated that a discrete class of ligands induced 
distinct conformations in the AF-2 domain that is 
responsible for interaction with cofactors (Brzozowski et 
al., 1997). This suggested that the discrete properties 
of ligands, through characteristic structures of ERs, 
eventually led to the modulation of interactions with 
cofactors. 
Taken together, I set up the hypothesis that ERs 
might recruit different repertoires of ER-interacting 
proteins (presumptive cofactors) depending on the 
ligands, the subtypes of ERs, and the cell/tissue types. 
Furthermore, this different repertoire of ER-interacting 
proteins could be one of the primary mechanisms to impose 
specificity of ER-mediated gene expression and eventually 
to explain the actions of SERMs. 
Here I describe my attempt to identify and compare 
the repertoire of nuclear proteins that interact with ERs 
depending on ligand, subtypes of ER and cell-types. I 
82 
employed GST pull down assays based on two earlier 
successful studies with nuclear receptors that: 1) 
identified ER interacting proteins such as ERAP 160 and 
ERAP 140 depending on the ligand (Halachmi et al., 1994) 
and 2) identified large groups of proteins such as DRIP 
complex (Rachez et al., 1998). To examine the subtype 
specificity, I decided to use GST-fused ERa full-length 
and GST-ER(3 full-length. The rationale for employing the 
full-length proteins was not only to detect both AF-1-
and AF-2- interacting proteins but also to avoid a simple 
reproduction of the previous report (Halachmi et al., 
1994). In an effort to examine cell-type specificity, I 
chose three representative cell lines: an MCF-7 breast 
cancer cell line in which TAM works as an antagonist, 
Ishikawa endometrial cancer cells in which TAM works as 
an agonist, and HeLa uterine cervical cell line as an ER 
negative cell. 
In this study, there seemed to be no major 
significant differences among three cell-types in the 
overall electrophoresis migration patterns of 
polypeptides interacting with GST-ERa LBD and GST-ER(3 
full-length in the presence of E2. A number of HeLa 
nuclear proteins interacting with GST-ER LBDs in the 
presence of E2 were isolated and identified. These 
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included TRAP/Mediator complex, which bound to both GST-
ERa LBD and GST-ER(3 LBD and several other proteins, which 
bound exclusively to GST-ERa LBD independently of 
TRAP/Mediator. 
3.2. Results 
3.2.1. Purification of ER interacting proteins 
The GST and GST-fused ERa full-length, ERa LBD 
(residues 302-595) and GST-ER(3 full-length were 
expressed, purified and immobilized on glutathione-
Sepharose beads as described in the Materials and 
Methods. After incubation with nuclear extracts derived 
from MCF-7 (Fig. 3-1A) or Ishikawa (Fig. 3-1B) or HeLa 
(Fig. 3-1C) cells in the presence or absence of 1 \xK E2, 
beads were washed extensively and bound proteins eluted 
and analyzed by SDS-PAGE followed by silver staining. 
As shown in Fig 3-1, a large number of polypeptides 
(circa 30 to 40 in each case) were found to interact with 
GST-ERa LBD and GST-ER(3 full-length in the presence of 1 
uM E2 (lanes 4 and 9 in Fig. 3-1A and 3-1C, lanes 4 and 8 
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Fig. 3-1. E2-dependent interactions of nuclear extract 
proteins with ERa full-length, ERa LBD and ER(3 full-
length. Nuclear extracts were derived from MCF-7 (A), 
Ishikawa (B) and HeLa (C) cell lines. Immobilized GST 
(lanes 1 and 2), GST-ERaLBD (lanes 3 and 4) and GST-
ERpLBD (lanes 8 and 9 in A and C, lanes 7 and 8 in B) 
proteins were incubated with nuclear extract in the 
absence (-) or presence ( + ) of 1 fxM E2 and bound proteins 
were eluted and analyzed by SDS-PAGE and silver staining 
as described in Materials and Methods. Purified 
TRAP/Mediator complex from f:Nut2 expressing cells was 
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in figure 3-1B). There were a number of polypeptides 
interacting with GST-ERa LBD and GST-ER(3 full-length in 
the absence of E2 (lanes 3 and 8 in Fig. 3-1A and 3-1C, 
lanes 3 and 7 in figure 3-1B), but most of them appeared 
with the GST alone and thus appeared to be nonspecific. 
The results of the GST-pull down assays with GST-ERa 
full-length were not easy to interpret clearly- This was 
most probably due to the degradation of GST-ERa full-
length proteins, which was seen in the isolated GST-ERa 
full-length proteins alone. 
Regarding cell-type specificity, there seemed to be 
no major significant difference among three cell-types in 
the overall electrophoretic migration pattern of the 
prominent polypeptides interacting with GST-ERa LBD in 
the presence of E2 (see below for the detailed 
description in case of HeLa). However, the further 
analyses are required to establish cell-type dependent 
differences in the identity of these polypeptides. 
Although there appeared to be some variations depending 
on the cell types in the absence of ligand, these were 
most likely due to slight variations in the amounts of 
GST fused proteins used in each this particular 
experiment. Again, this also needs to be clarified by 
further studies. 
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Concerning subtype specificity, direct comparisons 
were not possible due to difficulty in interpreting the 
results with the GST-ERa full-length. However, comparison 
of the results with GST-ERa LBD and GST-ER(3 full-length 
revealed that circa twenty polypeptides were found to 
interact with both GST-fused proteins in the presence of 
E2 although they showed stronger interactons with GST-ERa 
LBD than with GST-ER(3 full-length. Interestingly, there 
were circa 15 polypeptides bound, seemingly specifically, 
to GST-ERa LBD in the presence of E2. The results with 
GST-ERa LBD were different from the previous reports 
using a similar assay identified either only two proteins 
or almost nothing (Halachmi et al., 1994; Rachez et al., 
1998). This difference might be due to different 
constructs of GST-ERa LBD [302-595 in this study v.s. 
312-595 in the previous study (Rachez et al., 1998)] and 
probable variation of assay condition [although I 
followed the procedure as described previously (Rachez et 
al., 1998)]. For further characterization of this 
preliminary result, I decided to use HeLa nuclear extract 
because of practical reasons and GST-ER LBDs because of 
the failure to get clear results with the GST-ERa full-
length. Thus, I generated a corresponding ER(3 LBD 
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(residues 243-530) fused to GST to compare with the GST-
ERa LBD for receptor subtype specificity. 
3.2.2. A number of nuclear proteins interact with ER 
To characterize the proteins bound to GST-ER LBDs, 
GST-pull down assays were carried out essentially as 
described above except GST-fused ERa (residues 302-595) 
and ER(3 (residues 243-530) LBDs were used with HeLa 
nuclear extract in the presence and absence of E2. 
As shown in Fig. 3-2, circa 5 proteins bound 
specifically but quite weakly to GST-ERa LBD (lane 3) and 
circa 10 proteins bound specifically but weakly to GST-
ER(3 LBD (lane 7), relative to GST alone, in an E2-
independent manner (lanes 3 and 7); and these proteins 
largely (but not completely) overlapped for ERa and ER(3. 
Much larger groups of proteins (circa 30-40 in each 
case) showed E2-dependent interactions with the GST-LBDs 
(lanes 4 and 6) and these also largely (but not 
completely) overlapped for ERa and ER(3. Many of the 
polypeptides commonly associated with both GST-ER LBDs in 
the presence of E2 appeared similar in size to components 
of the circa 25-subunit TRAP/Mediator complex. This was 
further indicated by a direct comparison of the 
independently purified TRAP/Mediator complex (which 
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Fig. 3-2. E2-dependent interactions of HeLa nuclear 
extract proteins with ERa and ER(3 LBDs. Immobilized GST 
(lanes 2 and 8), GST-ERaLBD (lanes 3 and 4) and GST-
ERI3LBD (lanes 6 and 7) proteins were incubated with HeLa 
nuclear extract in the absence (-) or presence (+) of 1 
U.M E2 and bound proteins were eluted and analyzed by SDS-
PAGE and silver staining as described in Materials and 
Methods. Purified TRAP/Mediator complex from f:Nut2 
expressing cells was analyzed in lane 5. Standard 
molecular weight markers with sizes in kDa indicated on 
the left were present in lane 1. Bands marked with an 
asterisk represent degradation products of GST-ER fusion 
proteins. 
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contains some polypeptides that non-specifically bind to 
M2 agarose; and lane 2 in Fig. 4-8A) and subsequent 
analysis of TRAP/Mediator subunit interactions with the 
LBDs by western blot (see chapter 4). 
To further identify other prominent proteins 
interacting seemingly specifically with GST-ERa LBD in 
the presence of E2, mass spectral analyses was employed 
in collaboration with Wenzhu Zhang, at the laboratory of 
Brian Chait. Wenzhu Zhang characterized most of the 
polypeptides interacting with GST-ERa LBD in the presence 
of E2. These analyses confirmed the presence of specific 
TRAPS (e.g. TRAP220, TRAP170, hSUR2, PAQ/TIG1, TRAP95, 
TRAP80, p37, p36, MED6 and hSOHl) and further revealed 
many other known proteins as detailed in Figure 3-3. 
3.2.3. TRAP/Mediator-independent population(s) in ER LBD-
interacting proteins 
The observation of variations in stoichiometry of 
ER-LBD interacting proteins and the existence of 
TRAP/Mediator as one biochemically stable complex (Gu et 
al., 1999) hinted at their independent binding to ER 
LBDs. However, the simultaneous interaction of these 
proteins with GST-ERa LBD raised questions regarding the 
possible cooperativity in their interactions and 
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Fig. 3-3. Composition of E2-dependent ERa LBD-interacting 
proteins. Identity of proteins is determined by mass 
spectral analysis. 
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functions: 1) Does TRAP/Mediator interact with GST-ERa 
LBD directly or through other proteins in the total 
population or vice versa? ; 2) Is the interaction of 
TRAP/Mediator enhanced by other proteins in the 
population or vice versa? Independent binding rather than 
interdependent binding was suggested by further analyses 
showing a direct physical interaction between ERs and 
TRAP/Mediator complex (see below). However, this did not 
exclude the possibility of an essential role for 
TRAP/Mediator in the interaction of the other population 
of the proteins with GST-ERa LBD. This question was 
solved partly by the GST-pull down assays with nuclear 
extracts derived from wild type (WT) and TRAP220"/" mouse 
embryo fibroblasts (MEFs) that were originally isolated 
to assess the role for TRAP220 (see below). 
As shown in Fig. 3-4, the overall electrophoretic 
migration patterns of the murine polypeptides interacting 
in the presence of E2 with GST-ERa LBD from WT MEF 
nuclear extracts was very similar to that of the human 
ones (lane 3 in Fig. 3-4 vs lane 4 in Fig.3-2). This was 
confirmed by mass-spectral analyses by Wenzhu Zhang. The 
analyses with TRAP220-/- MEF-derived nuclear extracts 
revealed that most of the polypeptides other than 
TRAP/Mediator retained on GST-fused ER LBDs in an E2-
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Fig. 3-4. TRAP/Mediator-independent interactions of 
proteins with ER LBDs in nuclear extract. Immobilized GST 
(lanes 1 and 12), GST-ERa LBD (lanes 2, 3, 5, and 6) and 
GST-ER(3 LBD (lanes 7, 8, 10,11) were incubated with the 
nuclear extracts from wild type (WT) (lanes 1, 2,3,7 and 
8) and TRAP22 0~/~(KO) MEFs (lanes 5,6,10,11 and 12) in the 
absence (-) or presence ( + ) of 1 |a,M E2 and bound proteins 
were eluted and analyzed by SDS-PAGE and silver staining 
as detailed in Materials and Methods. TRAP/Mediator 
complexes immunopurified from cells expressing f:Nut2 are 
shown lanes 4 and 9. 
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dependent manner, thus indicating that these polypeptides 
bound to GST-ER LBDs independently of TRAP/Mediator 
complex. Moreover, the observation that the intensity of 
the interaction was not affected by the absence of 
TRAP/Mediator complex also suggested independent binding 
rather than cooperativity. 
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Chapter 4 
The TRAP/Mediator Coactivator Complex Interacts 
Directly with ER a and ER |3 and Directly Enhances ER 
Function In Vitro 
99 
4.1. Introduction 
As mentioned in chapter 3, as a part of a broader 
effort to identify novel ER-interacting factors 
(presumptive cofactors) that might show specificity for 
ERa and (3 subtypes and/or mediate tissue selective 
functions of SERMs (reviewed in McDonnell, 1999), I found 
E2-dependent interactions of the complete TRAP/Mediator 
complex with both ERa and ER(3. 
TRAP/Mediator complex was first identified through a 
ligand-dependent intracellular association with thyroid 
hormone receptor (TR) and shown to be essential for TR 
function on DNA templates in a reconstituted cell free 
system (Fondell et al., 1996). Subsequent isolation of 
the DRIP complex, apparently identical to TRAP/Mediator 
complex, extended its specificity for VDR through a 
ligand-dependent interaction with GST-VDR LBD (Rachez et 
al., 1998). However, the functional involvement of 
TRAP/Mediator complex in the action of class I (steroid 
hormone) nuclear receptors was not as well established as 
class II nuclear receptors such as TR and VDR. Despite 
the strong body of evidence indicating the significance 
of TRAP220 subunit in ER function (see below), it was 
suspected that ER might not interact with or coactivate 
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through intact TRAP/Mediator complex because of the 
following; (1) a failure to detect interaction of DRIP 
complex with ERaLBD in their GST-pull down assays (Rachez 
et al., 1998), (2) subsequent failures to demonstrate the 
interaction between ERs and the intact TRAP/Mediator 
complex by Freedman and his colleagues (Burakov et al., 
2000) and by Chao-Xing Yuan (unpublished observation) 
using immunoaffinity purification assays from the cell 
lines expressing epitope tagged ER alpha. In fact, one of 
the latter studies suggested that ER might function 
through TRAP220 alone or through a different TRAP220 
(sub)complex (Burakov et al., 2000). 
The study described here firmly established the role 
for the intact TRAP/Mediator complex in ER dependent 
transcription by showing that the interactions between 
TRAP/Mediator and ERs are direct and dependent on the ER 
LBD (but apparently modulated by the AF-1 domain) and 
that TRAP/Mediator can directly facilitates ER function 
in a cell-free system. This was the first report on the 
functional involvement of the intact TRAP/Mediator 
complex in the actions of class I (steroid hormone) 
nuclear receptors and further supported the notion that 
TRAP/Mediator is the general cofactor. 
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4.2. Results 
4.2.1. Estrogen-dependent Interactions of TRAP/Mediator 
with ER LBDs in Nuclear Extracts 
To extend the analyses of Fig. 3-2, proteins bound 
to ER LBDs in the presence and absence of E2 were 
analyzed by western blot with antibodies to a more 
comprehensive set of TRAP/Mediator components. As shown 
in Fig. 4-1, and by comparison with purified TRAP 
(f:Nut2) and TR-TRAP (f:TR) complexes, all TRAP/Mediator 
components examined (other than TRAP150, which may not be 
a bona fide integral subunit) were found to associate 
with ERa and ER(3 LBDs in an E2-dependent manner. As 
equimolar amounts of immobilized fusion proteins were 
used for the binding assays, the results also confirmed a 
stronger interaction of TRAP/Mediator complex with the 
isolated ERa LBD than with the isolated ER(3 LBD. The 
assays in Fig.4-1 further showed ligand-dependent 
interactions of SRC-1 and p300 with ER LBDs. As observed 
for TRAP/Mediator, these interactions are stronger for 
ERa than for ER|3. Consistent with the results of our 
previous analyses of TRAP/Mediator complexes (Gu et al., 
1999; Malik et al., 2000), and indicative of specificity 
of factor binding to ER LBDs, no interactions of general 
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Fig. 4-1. E2-dependent interactions of TRAP/Mediator 
with ERa and ER(3 LBDs in nuclear extract. Immobilized GST 
(lane 2), GST-ERaAB (lane 3), GST-ERaLBD (lanes 4 and 5), 
GST-ERf3AB (lane 6) and GST-ER|3LBD (lanes 7 and 8) 
proteins were incubated with HeLa nuclear extract in the 
absence (-) or presence ( + ) of 1 uM E2 and bound proteins 
were eluted and analyzed by SDS-PAGE and western blot 
(with antibodies to proteins indicated on the left) as 
described in Materials and Methods. One-tenth equivalent 
of the input nuclear extract is shown in lane 1. 
TRAP/Mediator and TR-TRAP complexes immunopurified from 
cells expressing f:Nut2 and f:TR respectively, are shown 
lanes 9 and 10. The band observed in lane 6 with MED7 
antibody is a nonspecific band that cross-reacts with 
this antibody. 
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transcription factors TFIIE (IIEa) and TFIIF (RAP30) were 
observed. 
Also of note is the lack of any detectable binding 
of TRAP/Mediator components to GST-fused ERaAB and ERpAB 
regions that contain the AF-1 domains (Fig. 4-1). This is 
consistent with the observation that the isolated TRAP220 
showed no detectable interaction with ER AF-1 but with ER 
AF-2 (Burakov et al., 2000). This result contrasts with 
reports that other nuclear receptor coactivators, 
including pl60/SRC members, can interact not only with 
AF-2 domains in a ligand-dependent manner but also with 
AF-1 domains in a ligand-independent manner (Webb et al., 
1998). It is notable, however, that in our assays 
interactions of these components (at normal nuclear 
levels) with ERaAB and ER(3 AB domains were either 
undetectable (p300) or barely detectable (SRC-1). The 
inability to see TRAP/Mediator interactions with AB 
domains also contrasts with the demonstration of a 
ligand-independent interaction of independently expressed 
TRAP170 with the AF-1 domain of the glucocorticoid 
receptor (Hittelman et al., 1999). However, these results 
do not exclude possible modulatory effects of AB and 
associated AF-1 domains on interactions of TRAP/Mediator 
with LBD and associated AF-2 domains. 
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4.2.2. Direct Interactions of Purified TRAP/Mediator 
complex with ER LBDs 
The studies described above have clearly shown 
ligand-dependent interactions of TRAP/Mediator with ER 
LBDs but, since they utilized nuclear extracts as a 
source of TRAP/Mediator, did not establish whether other 
factors were essential for these interactions. To further 
investigate this question, I employed a highly purified 
TRAP/Mediator complex immunopurified from cells 
expressing a FLAG-tagged SRB10/CDK8 subunit (Gu et al., 
1999). As shown in Fig. 4-2, this complex showed an E2-
dependent interaction with the ERa LBD and an E2-enhanced 
interaction with the ER(3 LBD. Overall interactions in the 
presence of E2 were again stronger for ERa than for 
ER|3, as in the analyses with nuclear extracts (above). 
Although I do not know the basis for the decreased 
ligand-dependency of the ER(3 LBD interaction with 
purified TRAP/Mediator, relative to TRAP/Mediator in 
nuclear extracts (above), this may reflect the absence of 
negative constraints (interacting factors) that increase 
the ligand-dependency of interactions in nuclear 
extracts. This observation is also consistent with the 
observation of ligand-dependent interactions of ER(3 with 
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Fig. 4-2. Direct interactions of purified TRAP/Mediator 
with LBDs of ERa and ER(3. Immobilized GST (lanes 6 and 
7), GST-ERa LBD (lanes 2 and 3) and GST-ER(3 LBD (lanes 4 
and 5) were incubated with immunopurified TRAP/Mediator 
complex from cells expressing f:CDK8/SRB10 in the absence 
(-) or presence ( + ) of 1 \xM E2. After extensive washing, 
bound proteins were eluted and analyzed by SDS-PAGE and 
western blot (with antibodies to proteins indicated on 
the left) as described in Materials and Methods. One-
tenth equivalent of the input TRAP/Mediator preparation 
was analyzed in lane 1. 
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Fig. 4-3. Intracellular association of TRAP/Mediator with 
ERaAAB. C8 cells that express FLAG-tagged ERa lacking the 
AB domain (f:hERaAAB) were maintained in DME-P04 media 
supplemented with 10% calf serum, f:ERaAAB and associated 
proteins were affinity-purified from C8-derived nuclear 
extract on M2 agarose. Proteins bound in the presence 
( + ) or absence (-) of 1 uM E2 during purification were 
eluted with FLAG peptide and analyzed by SDS-PAGE and 
western blot with antibodies to proteins indicated on the 
left. M2 agarose-bound proteins from HeLa extract were 
analyzed in lane 1 and one-tenth equivalent of C8 nuclear 
extract input was analyzed in lane 4. 
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a TRAP220 fragment in gel shift assays (Warnmark et al., 
2001). 
4.2.3. Intracellular Association of TRAP/Mediator with 
ERaAAB 
To provide evidence for a physiological association 
of ER with TRAP/Mediator, as previously demonstrated for 
TR (Fondell et al., 1996), I isolated FLAG-tagged ERaAAB 
(f:hERaAAB) and associated proteins through affinity-
purification from C8-derived nuclear extracts on M2 
agarose beads. The C8 cell line, established by Chao-Xing 
Yuan, is a HeLa-derived cell line that stably expresses a 
FLAG-tagged ERa lacking the AB domain (ERaAAB). A western 
blot of the bound and eluted proteins revealed the 
presence of FLAG-tagged ERaAAB (scored by both ERa and 
FLAG antibodies) as well as all TRAP/Mediator components 
that were analyzed (Fig. 4-3). An intracellular 
association of ERaAAB with p300 was also detected. None 
of these proteins were bound to M2 agarose when a control 
extract from HeLa cells was applied. These results thus 
indicate an intracellular association of the entire 
TRAP/Mediator complex with ER, as originally described 
for TR. 
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In the current analysis the probable E2-dependence 
of this association could not be assessed, as the C8 
cells lost receptors and exhibited poor viability in 
steroid-depleted media; and while purification of the 
ERaAAB-containing complex in the presence and absence of 
E2 yielded comparable results (Fig. 4-3, lane 2 vs. lane 
3), this likely reflects prior occupancy and stability of 
the ER ligand binding pocket by estrogen or estrogen-like 
compounds in the culture media. 
4.2.4. Roles for TRAP/Mediator In ER Function In nuclear 
extract. 
TRAP/Mediator has been shown to enhance the transcription 
activity of several activators, including nuclear 
receptors, from DNA templates in purified cell free 
systems (Fondell et al., 1996; Gu et al., 1999; Ito et 
al., 2000). To assess the role of the complete 
TRAP/Mediator complex in ER-mediated transcription, I 
employed a cell free system with TRAP/Mediator depleted 
nuclear extracts provided by Hwa Jin Baek (Baek et al., 
2002), combinations of baculovirus-expressed and purified 
GAL4-ER LBDs consisting of the DNA binding domain of the 
yeast activator GAL4 fused to the ER LBD (Fig.4-4) and 
affinity purified TRAP/Mediator from f:Nut2-derived 
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Fig. 4-4. Recombinant FLAG-tagged GAL4-ER LBD proteins. 
Affinity purified GAL4-ER LBD proteins were analyzed by 
SDS-PAGE and by either Coomassie Brilliant Blue R-250 
staining (left panel) or western blot with anti-FLAG 
antibody (right panel). 
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nuclear extract and a DNA template containing five copies 
of an GAL4 binding sites upstream of the adenovirus major 
late core promoter (Kundu et al. , 2000). The rationale 
for this approach was: 1) a previous study showing that 
GAL4-fused ERa LBD activates transcription in a ligand-
dependent manner in cell-based assays (Webster et al., 
1988); 2) the previous studies showing the function of ER 
in an in vitro transcription assay using GAL4-fused ERa 
LBD in conjuntion with crude nuclear extracts from naked 
DNA templates (Webster et al., 1988; Jacq et al., 1994) 
in contrast to the failure of full-length ER proteins in 
the same system (unpublished observation by myself and 
Chao-Xing Yuan); and 3) previous studies assessing the 
activity of TRAP/Mediator in a depleted nuclear extract 
system presumably containing a more normal complement of 
nuclear factors (Baek et al., 2002). In this assay (Fig. 
4-5), GAL4-ERa LBD (lanes 1 and 2) activated 
transcription weakly (circa 2-fold) and GAL4-ER(3 LBD 
(lanes 8 and 9) activated circa 4-fold in untreated 
nuclear extracts. By contrast, in the TRAP/Mediator-
depleted nuclear extract (ATRAP/MED) the absolute levels 
of activated transcription were completely reduced to the 
basal level (lanes 3 and 4, and lanes 10 and 11). Also of 
note, the levels of basal (activator-independent) 
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Fig. 4-5. Requirement of TRAP/ Mediator for 
transcriptional activity of GAL4-ER LBDs in nuclear 
extract. Transcription activation by GAL4-ER LBDs is 
suppressed in the a-TRAP25 antibody-depleted nuclear 
extract. In vitro transcription reactions contained 20 \xq 
each nuclear extract (lanes 1,2,8,9: untreated; lanes 3-
7,10-13: a-TRAP25 antibody-depleted) and 50 ng each of 
pA53 and pG5A53 templates, respectively. The 
transcription reactions in lanes 1-7 and lanes 8-13 
additionally contained 10 ng of recombinant GAL4-ERa LBD 
and GAL4-ER(3 LBD respectively. Increasing amount of 
purified TRAP/ Mediator (lanes 5-7 and lanes 12,13) were 
added to a-TRAP2 5 antibody-depleted nuclear extract in in 
vitro transcription reactions. As determined by 
immunoblotting, the amount of TRAP/ Mediator added to the 
reactions corresponded to approximately 100 % (lanes 
5,12) or 200 % (lanes 6,13) or 400 % (lane 7) of the of 
the TRAP/ Mediator concentration in untreated nuclear 
extract. Relative transcription levels, determined by 
phosphorimaging, are indicated. 
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transcription (lanes 1 vs.3 and lanes 8 vs.10) were 
decreased upon depletion of TRAP/Mediator as reported 
previously (Baek et al., 2002). Upon addition of 
increasing amounts of TRAP/Mediator to depleted extract, 
activated transcription was, in a dose-dependent manner, 
enhanced up to seven-fold in the case of GAL4-ERa LBD and 
up to twenty-fold in the case of GAL4-ER(3 LBD. This 
indication that an excess amount of ectopic TRAP/Mediator 
can enhance activated transcription by GAL4-ER LBDs 
beyond the level seen in the control extract suggests 
that TRAP/Mediator is a limiting cofactor for ER 
function. These results clearly demonstrated a role for 
TRAP/Mediator in ER-LBD function, as well as a greater 
activity for ER(3 LBD than for ERa LBD (lanes 2 vs. 9 and 
lanes 6 vs.13). In addition, the relative responses of ER 
LBDs to the ectopic TRAP/Mediator correlate with the 
intrinsic affinity of ER LBDs for TRAP/Mediator. 
4.2.5. Interactions of TRAP/Mediator with Intact ERs. 
The above results have established E2-dependent 
interactions of TRAP/Mediator with isolated ER LBDs, but 
these interactions can be considered physiologically 
relevant only if they are demonstrable in the context of 
natural full-length receptors. In an analysis of this 
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question, full-length FLAG-tagged ERs were expressed via 
baculovirus vectors, affinity purified and immobilized on 
M2 agarose beads (Fig.4-6). Nuclear extracts were applied 
to beads containing immobilized receptors, and after 
washing bound proteins were eluted and analyzed by SDS-
PAGE and western blotting with antibodies to 
representative TRAP/Mediator components. As indicated in 
Fig. 4-7, TRAP/Mediator bound to both ERa and ER(3 in an 
E2-dependent manner. However, in contrast to the results 
with ER-LBDs, TRAP/Mediator showed stronger interactions 
with ER(3 than with ERa. Although not directly comparable, 
these results are nonetheless consistent with a prior 
report that isolated TRAP220 interacts more strongly with 
intact ER(3 than with ERa (Warnmark et al., 2001). Given 
that the assays for TRAP/Mediator interactions with 
intact ERs (Fig.4-7) versus ER LBDs (Fig. 4-1) were 
performed under comparable conditions, these results 
suggest that the ERa and ER(3 AB domains differentially 
modulate interactions of TRAP/Mediator with corresponding 
LBDs. 
To investigate the possibility that additional 
nuclear proteins might have facilitated intact ER-
TRAP/Mediator interactions in these assays, the binding 
of 35S-labelled full length ER(3 to purified and 
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Fig. 4-6. Recombinant FLAG-tagged ER proteins. Affinity 
purified ERs were analyzed by SDS-PAGE and by either 
Coomassie Brilliant Blue R-250 staining (lanes 1 and 2) 
or western blot with corresponding antibodies (lanes 3 
and 4). 
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Fig. 4-7. E2-dependent interactions between TRAP/Mediator 
and ERs in HeLa nuclear extract. M2 agarose-immobilized 
FLAG-ERa (lanes 3 and 4) and FLAG-ER(3 (lanes 5 and 6) were 
incubated with HeLa nuclear extracts in the absence (-) 
or presence ( + ) of 1 u.M E2 and bound proteins were eluted 
with FLAG peptide and analyzed by SDS-PAGE and western 
blot (with antibodies to proteins indicated in the left) 
as described in Materials and Methods. As a control, HeLa 
nuclear extract proteins bound to M2 agarose alone were 
analyzed in lane 2. One-tenth of input nuclear extract 
was analyzed in lane 1. 
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immobilized TRAP/Mediator (Fig.4-8A) was analyzed. For 
technical reasons relating to the presence of FLAG tags 
both on recombinant ERs and on the purified TRAP complex, 
an analysis of TRAP/Mediator binding to M2 agarose-
immobilized ERs was not possible. As shown in Fig. 4-8B, 
35S-labelled full length ER(3 bound to purified 
TRAP/Mediator, thus indicating direct ER-TRAP/Mediator 
interactions. 
4.2.6. TRAP/Mediator Directly Enhances ER Function In a 
Purified In Vitro Transcription Assay. 
TRAP/Mediator has been shown to enhance the 
transcription activity of several activators, including 
nuclear receptors, from DNA templates in purified cell 
free systems (Fondell et al., 1996; Gu et al., 1999; Ito 
et al., 2000). The role of the complete TRAP/Mediator 
complex in ER-mediated transcription, was further 
assessed, in collaboration with Mohamed Guermah, in a 
cell free system reconstituted with highly purified 
general initiation factors and cofactors (TFIIB, TFIID, 
TFIIE, TFIIF, TFIIH, RNA polymerase II and PC4), 
combinations of baculovirus-expressed and purified 
receptors (Fig.4-6) and affinity purified TRAP/Mediator 
(Fig.4-8A lane 2), and a DNA template containing four 
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Fig. 4-8. E2-dependent interactions between purified 
TRAP/Mediator and full-length ER|3. A. Purified 
f:TRAP220AB TRAP/Mediator complex. The complex was 
affinity purified from cells expressing a FLAG-tagged 
TRAP2 2 0 lacked the C-terminal domain (f:TRAP2 2 0AB) and 
analyzed by SDS-PAGE and silver staining (lane 2). Lane 1 
shows HeLa nuclear extract proteins bound non-
specifically to M2 agarose. B. Direct interactions 
between purified TRAP/Mediator complex and full-length 
ER(3. M2 agarose immobilized TRAP/Mediator (f :TRAP2 2 0AB) 
complex (lanes 3,4 and 6) and M2 agarose alone (lanes 2 
and 5) were incubated with 35S-labeled (in vitro 
translated) full length ER(3 in the presence (lane 3) or 
absence (lane 4) of 1 \xM E2 or with control lysate (lanes 
5 and 6). After washing, bound proteins were eluted with 
FLAG peptide and analyzed by autoradiography (upper 
panel) or by western blot with antibodies to the 
indicated components of TRAP/Mediator complex (lower 
panel). Lane 1 shows one-twentieth of the 35S-labeled full 
length ER(3 input. 
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copies of an estrogen response element (ERE) upstream of 
the adenovirus major late core promoter (Wu et al., 
1999). In this assay (Fig. 4-9), basal activity (lane 1) 
was unaffected by ERa alone (lane 3) and weakly (circa 
2-fold) enhanced by ER(3 alone (lane 4) or by 
TRAP/Mediator alone (lane 2). In the presence of 
TRAP/Mediator, activity with ERa was about five-fold 
above basal (lane 5) and activity with ER(3 was about 20-
fold above basal (lane 6). These results clearly show a 
direct role for TRAP/Mediator in ER function, as well as 
a greater activity for ER(3 than for ERa as the equimoloar 
amounts of ERs were used for this assay. While somewhat 
surprising, the latter result is consistent with the 
higher affinity of TRAP/Mediator for intact ER(3 relative 
to intact ERa considering the fact that ERa showed the 
stronger DNA binding activity than ER(3 (data not 
included). 
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Fig. 4-9. TRAP/Mediator complex directly mediates ER 
function in vitro. Reactions contained purified general 
transcription factors and cofactors, purified 
TRAP/Mediator complex and ER proteins (20 nM) as 
indicated, and both 4EREA53 G-less reporter and ML200 G-
less control templates. TRAP/Mediator was purified from 
the cell line expressing f:TRAP220AB (Fig. 4-8A lane 2). 
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Role of TRAP220 subunit in ER Function 
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5.1. Introduction 
The significance of TRAP220 subunit in Nuclear 
receptor function has been well established by studies 
showing: 1) original isolations through its direct 
interaction with TR (Lee et al., 1995) and PPARy(Zhu et 
al., 1997) in yeast two-hybrid assays; 2) ligand-
dependent interactions of TRAP22 0 with a number of other 
nuclear receptors, further suggesting a broader role for 
TRAP2 2 0 through TRAP/Mediator in nuclear receptor 
function (Yang et al., 2000; Rachez et al., 1999; Yuan et 
al., 1998 ; Zhu et al., 1997); 3) defective cellular 
functions of various receptors in response to dominant 
negative mutant form of TRAP220 (Yuan et al., 1998; Zhu 
et al., 1997); 4) significant physiological defects 
including receptor function upon deletion of TRAP220 (Ito 
et al., 2000; Shao et al., 2000; Zhu et al., 2000; Ge et 
al., 2002). 
Despite the lack of any direct evidence for the role 
for the TRAP/Mediator complex in ER function, a number of 
studies suggested the potential involvement of TRAP220 
subunit in ER function. Chao-Xing Yuan first observed a 
ligand-dependent interaction of intact TRAP22 0 with ERa 
although it was very weak compared to other receptors 
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(Yuan et al., 1998). Subsequent studies confirmed 
physical interactions of TRAP220 with ERa (Burakov et 
al., 2000; Warnmark et al., 2001; Zhu et al., 1999), 
demonstrated inhibitory effects of an ER-interacting 
fragment of TRAP220 (Burakov et al., 2000) and an anti-
TRAP220 antibody on ERa function in transfected cells, 
and established the presence of TRAP220 on the promoters 
of endogenous estrogen-responsive genes (Shang et al. , 
2000). However, interpretation of these studies was 
complicated by (1) the stable association of TRAP220 with 
other TRAP/Mediator components that may mediate (via 
different activators not ER) TRAP/Mediator recruitment 
and function; (2) the failure to analyze suitable control 
genes and other cofactors for broader effects of agents 
designed to block TRAP220 functions; and (3) some 
discrepancy regarding the ability of TRAP220 to interact 
with ERa vs. ER(3 (mentioned in Kang et al., 2002). 
Not surprisingly, TRAP220 contains two LXXLL motifs 
that are found in most of nuclear receptor cofactors and 
responsible for the interaction with nuclear receptors. 
The LXXLL motif has been suggested to play roles in 
determining specificity from the observation that 
different LXXLL motif is required for the interaction 
with specific nuclear receptors. Consistent with this 
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idea, the second (closer to C-terminal) LXXLL motif (NR 
box2) in TRAP220/DRIP205 was essential for the 
interaction with VDR and TR, whereas the first (more N-
terminal) motif (NR boxl) was dispensible (Yuan et al., 
1998; Rachez et al., 2000). 
Here I characterized a role for TRAP220 in ER 
function. I showed that TRAP220 is an essential anchor 
for a strong interaction between ER and TRAP/Mediator. I 
further demonstrated that both NR boxes within TRAP2 2 0 
are important for mediating an interaction between ER and 
the TRAP/Mediator complex. I also describe my preliminary 
studies on the function of TRAP220 and its NR boxes in 
ER-dependent transcription. 
5.2. Results 
5.2.1. TRAP220-dependent Interactions of TRAP/Mediator 
with ER LBDs in Nuclear Extracts. 
The demonstration of ligand-dependent interactions 
of ERa and ER(3 with isolated TRAP220 (Burakov et al. , 
2000; Warnmark et al., 2001; Yuan et al., 1998; Zhu et 
al., 1999) and the observation that TRAP220 is a main 
subunit for strong ligand-dependent interactions of the 
TRAP/Mediator complex with nuclear receptors such as TR 
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and VDR (Yuan et al., 1998; Rachez et al., 1999), has led 
to speculation that TRAP2 2 0 may anchor ERs to the 
TRAP/Mediator complex. To address this issue, I employed 
GST pull down assays with nuclear extracts from MEFs 
derived from wild type and TRAP220-/- mice (Ito et al., 
2000). This approach is technically simpler than other 
alternative approaches such as a Far Western analysis 
employed for TR (Yuan et al., 1998). The availability of 
reagent further facilitated this assay. Furthermore, this 
assay can determine the role for TRAP22 0 in the observed 
ER-TRAP/Mediator interaction. As shown in Fig. 3-4 and 
Fig.5-1, TRAP/Mediator components from control MEFs bound 
in an E2-dependent manner to GST-fused ER LBDs whereas 
TRAP/Mediator components from TRAP2 2 0-/- MEFs did not. 
Other studies have shown that TRAP220-/-cells contain a 
residual TRAP complex lacking only TRAP220 and that this 
complex interacts normally with other activators such as 
VP16 (Chao-Xing Yuan and Sohail Malik unpublished 
observation). These results firmly establish an essential 
role for TRAP220 in strongly anchoring TRAP/Mediator to 
ERa and ER(3 and again show that TRAP/Mediator has a 
stronger affinity for the isolated ERa LBD than for the 
isolated ER(3 LBD in the context of other nuclear 
proteins. 
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Fig. 5-1. TRAP220-dependent interactions of TRAP/Mediator 
with ER LBDs in nuclear extract. Immobilized GST (lanes 2 
and 11), GST-ERa LBD (lanes 3-6) and GST-ER|3 LBD (lanes 
7-10) were incubated with the nuclear extracts from wild 
type (WT) (lanes 2,3,4,7 and 8) and TRAP22 0"/"(KO) MEFs 
(lanes 5,6,9,10 and 11) in the absence (-) or presence 
( + ) of 1 u.M E2 and bound proteins were eluted and 
analyzed by SDS-PAGE and western blot (with antibodies to 
proteins indicated on the left) as detailed in Materials 
and Methods. One-tenth equivalents of input nuclear 
extracts were analyzed in lanes 1 (WT) and 12 (KO). 
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5.2.2. Effect of TRAP220 on ER-driven transcriptional 
activation in TRAP220/~ MEFs. 
The essential requirement of TRAP220 for the ER-
TRAP/Mediator interaction raised the possibility that 
loss of TRAP220 could result in the failure to support 
ER-activated transcription. To examine this possibility, 
I carried out transfection assays with WT and TRAP220-/-
MEFs employed in the previous pull down assays. MEFs of 
each genotype were transfected with an ER expression 
vector and a reporter containing three ERE sites and core 
promoter. A strong E2 response (up to 80-fold induction) 
was observed in wild type cells. The response was 
attenuated only modestly (circa 2-fold), but very 
reproducibly, in TRAP220-/- MEFs (Fig. 5-2). 
Significantly, however, transcription in TRAP220-/- MEFs 
was restored to the wild-type level by simultaneous 
expression of ectopic TRAP220 (Fig. 5-3). While TRAP220 
is essential for optimal ER function in response to E2, 
the significant activation of ER-driven transcription in 
TRAP220-/- MEFs that suggests the existence of an 
alternative pathway(s) to support ER function or lack of 
proper restraint, which TRAP/Mediator is required to 
overcome (see discussion). 
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Fig. 5-2. Defect in ER-mediated transcription in TRAP220" 
/_MEFs. The MEFs of each genotype were transfected with 
indicated amounts of human ER, 3ERE-luciferase reporter, 
and control luciferase pRL-CMV. Cells were cultured in 
the absence (-) or presence ( + ) of the ligand, E2 (IO"8 
M), and dual luciferase activities were measured 36 hr 
after transfection. Values (means ± SD of a 
representative experiment performed in duplicate) are 
plotted as a fold. 
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Fig. 5-3. Complementation of defective ER-driven 
transcription in TRAP220-/- MEFs by exogenous TRAP220. 
The MEFs of each genotype were transfected with human ER, 
TRAP220, 3ERE-luciferase reporter, and control luciferase 
pRL-CMV. Cells were cultured in the absence (-) or 
presence ( + ) of the ligand, E2 (10 nM) , and dual 
luciferase activities were measured 36 hr after 
transfection. Values (means ± SD of a representative 
experiment performed in duplicate) are plotted as a fold. 
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5.2.3. NR box-dependent Interactions of isolated TRAP220 
with ER LBDs 
The differential requirement of each NR box in 
TRAP220 for the interaction with ERs had been suggested 
by the previous observations that deletion or mutation of 
NR1 in the fragment of TRAP220 (604-774) abolished or 
decreased interaction with ERa while deletion or mutation 
of NR2 (527-604) affected it to less extent (Burakov et 
al., 2000; Warnmark et al., 2001). However, these results 
can be considered physiologically relevant only if they 
are demonstrable in the context of natural full length 
TRAP220 and intact TRAP/Mediator complex. Prior to 
addressing this issue in the context of intact 
TRAP/Mediator complex, I examined the relevance of these 
results in the context of the N-terminal part of TRAP22 0 
(1-670), TRAP220 AB, on the basis of the following: 1) 
TRAP220 is essential for demonstrable interaction of ER 
with TRAP/Mediator; 2) availability of TRAP/Mediator 
complexes containing TRAP2 2 0AB or each mutant derived 
from TRAP220AB (right panel in Fig. 5-4); and 3) the 
transcriptional activity of TRAP/Mediator complex 
containing TRAP220AB to support TR function is equivalent 
to that of TRAP/Mediator containing full-length TRAP220 
(unpublished observation by Mohamed Guermah and Chao-Xing 
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Yuan). I employed GST pull down assays using GST-ER LBDs 
with 35S-labeled proteins expressed from the constructs 
(right panel in Fig. 5-4) harboring deletion mutants or 
point mutants of TRAP2 2 0AB (provided by Chao-Xing Yuan). 
Apart from TRAP220 NR mutants, I used various TRAP2 2 0AB 
mutants in order to examine the possible involvement of 
other part(s) of TRAP2 2 0 in the interaction between ER 
and TRAP2 2 0 because the previous experiments used only 
fragments of TRAP220 (Burakov et al., 2000). As shown in 
Fig. 5-4, most of the mutants exhibited strong 
interactions with GST-ER LBDs comparable to WT full-
length and AB fragment. In contrast, point mutations in 
either NR box significantly diminished the TRAP220 
interaction with ER LBD. Morevore, in contrast to the 
results of previous reports (Burakov et al., 2000; 
Warnmark et al., 2001), mutation in NR2 exhibited a more 
severe effect than in NR1. This might be due to the 
differences in assay conditions and/or TRAP220 constructs 
that were used. In addition, the interaction between GST-
ER LBDs and TRAP2 2 0AB with the mutations in both NR boxes 
was undetectable. 
Also of note, ERa LBD and ER(3 LBD seemed to bind to 
isolated TRAP220 similarly in this assay. This is 
consistent with the earlier study by Burakov et al but is 
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Fig. 5-4. NR box-dependent interactions of TRAP220 with 
ER LBDs. Immobilized GST (lanes 6), GST-ERa LBD (lanes 2 
and 3) and GST-ER^LBD (lanes 4 and 5) were incubated with 
35S-labeled (in vitro translated) TRAP220 proteins in the 
presence (lane 2 and 4) or absence (lane 3 and 5) of 1 [xM 
E2 and bound proteins were eluted and analyzed by SDS-
PAGE followed by autoradiography as detailed in Materials 
and Methods. Lane 1 shows one-seventh of the 35S-labeled 
TRAP22 0 input. 
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contrast to the study by Warnmark et al. More 
importantly, this result seems to be contrast to the 
result of many assays with nuclear extract and purified 
TRAP/Mediator complex. Although we do not know the reason 
yet this could be due to stimulatory effect of other 
Mediator components on the interaction of TRAP2 2 0 with 
ERa LBD and/or inhibitory effect on the interaction of 
TRAP22 0 with ER|3 LBD. 
5.2.4. NR box-dependent Interactions of purified 
TRAP/Mediator with full-length ERp" 
To analyze the observed role for the NR boxes in the 
context of the intact TRAP/Mediator complex and intact 
ER, I employed purified TRAP/Mediator complexes with 
full-length ER(3. As shown in Fig 5-5, TRAP/Mediators 
containing TRAP220a (NR1 mutant), TRAP220b (NR2 mutant) 
or TRAP2 2 0ab (NR1/NR2 double mutant) (f:a, f:b and f:ab 
respectively) all showed dramatic reductions (6-8 fold in 
each case) in their interactions with full-length 
ERp, compared to that of TRAP/Mediator complex containing 
TRAP2 2 0AB (f:AB). This indicated that the point mutations 
in either NR box significantly affect the interaction 
between intact TRAP/Mediator and ER(3 full-length and 
suggests that both NR boxes are important for the 
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Fig. 5-5. TRAP220 NR box-dependent interaction between 
purified TRAP/Mediator complex and full-length ER(3. M2 
agarose immobilized TRAP/Mediator (f:TRAP220AB, 
f:TRAP220a, f:TRAP220b and f:TRAP220ab) complexes (lanes 
3,4, 5 and 6) and M2 agarose alone (lane 2) were 
incubated with 35S-labeled (in vitro translated) full 
length ER(3 in the presence (lanes 2-6) of 1 \xH E2. After 
washing, bound proteins were eluted with FLAG peptide and 
analyzed by autoradiography (top panel) or by western 
blot with antibodies to the indicated components of 
TRAP/Mediator complex (lower panels). Lane 1 shows one-
seventh of the 35S-labeled full length ER(3 input. 
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interaction between intact TRAP/Mediator and ER(3 full-
length. 
5.2.5. Role for NR box of TRAP220 in ER-dependent 
transcription in TRAP220-/- MEFs 
To assess the role of the TRAP220 NR boxes in ER 
dependent transcription I employed transfection assays 
with MEFs previously utilized. MEFs of each genotype were 
transfected with an ER expression vector, a reporter 
containing three ERE sites with core promoter and 
expression vectors for full length TRAP220 either wild-
type or NR mutants. Simultaneous expression of ectopic 
full-length TRAP220 restored to the wild-type level while 
all the point mutants of TRAP220 did not (Fig. 5-6) 
although the expression level of each TRAP220 was 
comparable (data not included). This is consistent with 
the results from the interaction study. 
5.2.6. Role for NR box of TRAP220 in ER-dependent 
transcription in cell free transcription assay 
The observation of the modest defect in ER-driven 
transcription in TRAP220-/- MEFs raised the concern that 
this particular cell-based assay might not be able to 
fully recapitulate normal ER activation mechanisms and 
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Fig. 5-6. Role for TRAP 220 NR box in ER-driven 
transcription. The MEFs of each genotype were transfected 
with human ER, indicated TRAP220, 3ERE-luciferase 
reporter, and control luciferase pRL-CMV. Cells were 
cultured in the absence (-) or presence (+) of the 
ligand, E2 (IO"8 M) , and dual luciferase activities were 
measured 36 hr after transfection. Values (means ± SD of 
a representative experiment performed in duplicate) are 
plotted as a fold. 
150 
R o l e f o r T R A P 2 2 0 N R b o x in E R -






o (33 > 
p— 
O 
o CO > 
? 
O CM Cvj 
t_ 
o 
o CO > 
03 





o CM CM 
O 
o 03 > 
S3 





o CO > 15 
CE LU 
fc; 





















requirements for cofactors such as TRAP220. To extend the 
analysis, and given positve results in the previous 
observations (Fig.4-5 and Fig.4-9), I employed cell-free 
transcription assays with either TRAP/Mediator-depleted 
nuclear extract or a system reconstituted with purified 
factors. In the first case, depleted nuclear extracts 
lacking endogenous TRAP/Mediator were complemented with 
the affinity purified TRAP/Mediator complexes from 
f:TRAP220AB-, f:TRAP220a-, f:TRAP220b-, and f:TRAP220ab-
derived HeLa nuclear extracts. The inputs were normalized 
on the basis of their activity to support equivalent 
level of activation by GAL4-p5 3, which does not require 
TRAP2 2 0 for TRAP/Mediator interaction and function. As 
shown in Fig. 5-7, all the TRAP/Mediator complexes 
containing each TRAP2 2 0 mutant showed modest reduction 
(1.2 to 1.7 fold) in their ability to support the 
activated transcription by GAL4-ER(3 LBD in comparison 
with the TRAP/Mediator containing wild type TRAP220 AB. 
This is very reproducible and consistent with the results 
from transfection assays. In order to rule out the 
possible residual TRAP220 in the depleted nuclear 
extracts, I employed Namalwa nuclear extracts depleted 
TRAP/Mediator by anti-TRAP220 antibody. The composition 
of this assay system is essentially same as the system 
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Fig. 5-7. Role for TRAP220 NR box in ER-dependent 
transcription. In vitro transcription reactions contained 
2 0 [iq the a-TRAP2 5 antibody-depleted nuclear extract and 
17.5 ng of pA53 and 35ng of pG5A53 templates. The 
transcription reactions in lanes 1-10 and lanes 11-14 
additionally contained 10 ng of recombinant GAL4-ER(3 LBD 
and GAL4-p53 respectively. Each purified TRAP/ Mediator 
complex (f:TRAP220AB in lanes 3,4, and 11; f:TRAP220a in 
lanes 5,6, and 12; f:TRAP220b in lanes 7,8, and 
13;f:TRAP220ab in lanes 9,10 and 14) were added to a-
TRAP25 antibody-depleted nuclear extract in transcription 
reactions. Relative transcription levels, determined by 
phosphorimaging, are indicated. 
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shown in Fig. 5-7. In this assay (Fig. 5-8), the level of 
activated transcription by GAL4-ER(3 LBD was enhanced up 
to about 9 fold upon addition of TRAP/Mediator containing 
TRAP220 AB (f:AB) similar to previous experiment (Fig. 4-
5). TRAP/Mediator containing either double mutant 
TRAP220ab (f:ab) or no TRAP220 (provided by Sohail Malik) 
showed very modest reduction (1.5 fold) in their ability 
to support GAL4-ERP LBD-activated transcription. 
The discrepancy between the results from the 
interaction assays and the functional assays could be due 
to the following: 1) the existence of the alternative 
activation pathways to support ER dependent transcription 
such as other cofactors and/or 2) the lack of the 
constraints which impose a requirement for TRAP/Mediator 
to overcome such as chromatin blockade (see discussion). 
I employed transcription assay system reconstituted with 
highly purified factors because this system is so minimal 
that neither activation nor negative restraints present 
other than general transcription machinery. So if the 
first possibility is major then I should be able to see 
the difference in this sytem. The recombinant factors 
expressed in and purified from bacteria included TFIIB 
(one subunit [Fig. 5-9A, lanel]), TBP (lane 2), TFIIE 
(two subunits [lane 3]), TFIIF (two subunits [lane 4]) 
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Fig. 5-8. Role for TRAP220 in transcriptional activity of 
GAL4-ER(3 LBDs in nuclear extract. In vitro transcription 
reactions contained 20 \xq the a-TRAP25 antibody-depleted 
nuclear extract and 17.5 ng of pA53 and 35ng of pG5A53 
templates. The transcription reactions in lanes 1-4 and 
lanes 5-8 additionally contained 10 ng of recombinant 
GAL4-ER(3 LBD and GAL4-p53 respectively- Each purified 
TRAP/ Mediator complexes (f:TRAP220AB in lanes 2 and 6; 
f:TRAP220ab in lanes 3 and 7; and f:TRAP220-/- in lanes 4 
and 8) were added to a-TRAP25 antibody-depleted nuclear 
extract in transcription reactions. Relative 
transcription levels, determined by phosphorimaging, are 
indicated. 
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and PC4 (1 subunit [lane 5]). The multisubunit components 
purified from cell lines expressing FLAG-tagged subunits 
included f: Pol II (12 subunits [lane 7]), f:TFIID (-15 
subunits [lane 8]) and f:TFIIH (9 subunits [lane 9]). 
Recombinant GAL4-p53 was used as an activator to 
establish the functionality of this particular assay 
system. As shown in Fig. 5-9B, activation (up to 19-fold) 
by GAL4-p53 was achieved above the basal (activator 
independent) transcription (lane 1). This indicated that 
all purified factors are functional for transcription in 
my highly purified transcription system, based on the 
previous study showing the requirement of all the factors 
for the activated transcription (Yu et al., 2001). 
Consistent with the results from the nuclear extract 
based assay, all the TRAP/Mediator exhibited comparable 
ability to support ER dependent transcription. (Fig. 5-
10) 
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Fig. 5-9. Transcription activation by a model activator 
in a cell-free system reconstituted with purified 
factors. A. SDS-PAGE analysis of purified factors. 
Coomassie blue R250 staining of purified general 
initiation factors TFIIB, TBP, TFIIE, and TFIIF (lanes 1-
4) and general coactivator PC4 (lane 5) were performed. 
Silver staining of the immunopurified FLAG-tagged 
multisubunit general initiation factors TFIID and TFIIH 
and RNA polymerase II (lanes 7-9) performed. Lane 6 shows 
molecular weight markers(SM). B. Activator-dependent 
transcription. Transcription was conducted with the 
purified components shown in panel A, GAL4-p53 and the 
DNA template described previously. Fold activation above 
the basal level is indicated at the bottom. 
159 
T r a n s c r i p t i o n activation b y a m o d e l activator 
in a cell-free s y s t e m 
r e c o n s t i t u t e d w i t h purified f a c t o r s 
A. IIB TBP HE MF PC4 SM Pol II MD IIH 
200 11 
200 m-m • — Ir^i 
















«»• «* ] 
- - ** î Sr- -
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Fig. 5-10. Role for TRAP220 NR box in transcriptional 
activity of GAL4-ER|3 LBDs in nuclear extract. In vitro 
transcription reactions contained purified general 
transcription factors, 4EREA53 G-less reporter template 
and G5A53 G-less control template as described in 
Materials and Methods. Additionally, the transcription 
reactions contained 10 ng of GAL4-p53 in lanes 1-5, 20 nM 
of recombinant ERa in lanes 6-10 and 20 nM of recombinant 
ER|3 in lanes 11-15. Each purified TRAP/ Mediator complex 
(f:TRAP220AB in lanes 2,7, and 12; f:TRAP220a in lanes 
3,8, and 13; f:TRAP220b in lanes 4,9, and 14;f:TRAP220ab 
in lanes 5,10 and 15) were added to transcription 
reactions. Relative transcription levels, determined by 
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Identification of EDD/hHYD 
as an ER-interacting protein 
163 
6.1. Introduction 
The hyd gene has originally been isolated from 
Drosophila mutants showing hyperplastic discs phenotype 
(Mansfield et al., 1994). The 280kDa drosophila HYD 
protein shares high homology with lOOkD rat protein. This 
protein was found mainly in nuclear fraction (partly in 
cytosolic fraction) and expressed in all stages of 
development and all tissues (although varied levels of 
expression). Interestingly, this protein exhibited 
decreased expression in the mutants suggesting that it is 
a possible tumor suppressor. 
Later, its human homologue was identified as EDD (E3 
identified by differential display) by differential 
display for progestin-induced gene (Callaghan et al., 
1998). In contrast to the previous implication of its 
potential function as a tumor suppressor, breast cancers 
showed higher expression of this gene. However, the 
overexpressed proteins in cancer cells could be the 
dominant negative mutants of EDD as reported in the case 
of p53. EDD contains HECT (homologous to E6-AP C-
terminus) domain and can bind to Ubiquitin suggesting its 
function as E3 ligase in ubiquitylation. Subsequent study 
showed its E3 ligase activity both in vivo and in vitro 
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(Honda et al., 2002). Relevant to ubiquitylation, 
previous studies have shown the following: 1) ER is a 
ubiquitinated protein and level of ubiquitylation was 
different depending on ligands (Wijayaratne and 
McDonnell, 2001), 2) ER is regulated by proteasome 
pathway which may somehow be involved in ER 
transcriptional activity through modulation of cofactors 
(Lonard et al., 2000), and 3) E6-AP is an E3 ligase and 
showed coactivator activity for NR including ER (Nawaz et 
al., 1999). These studies, together with the finding that 
EDD/hHYD interacts with ERs, hinted at the possibility 
that this protein might play a role as an ER cofactor 
through its ubiquitin ligase activity. Here I describe 
the very preliminary studies on this possibility. 
EDD/hHYD interacts with both ERs in different manners. 
Overexpression of EDD/hHYD did show very modest effect on 
ER-driven transcription in transient transfection assays. 
6.2. Results 
6.2.1. HYD is an ER-interacting nuclear protein 
To extend mass spectral analysis described in chapter 
3.2, I employed western blot analysis with antibody 
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Fig. 6-1. EDD/hHYD is an ER-interacting nuclear protein. 
A. E2-dependent interactions of EDD/hHYD with ERa and ER(3 
LBDs in nuclear extract. Immobilized GST (lane 2), GST-
ERaAB (lane 3), GST-ERaLBD (lanes 4 and 5), GST-
ER|3AB (lane 6) and GST-ER(3LBD (lanes 7 and 8) proteins 
were incubated with HeLa nuclear extract in the absence 
(-) or presence (+) of 1 uM E2 and bound proteins were 
eluted and analyzed by SDS-PAGE and western blot with 
antibody against EDD/hHYD as described in Materials and 
Methods. One-tenth equivalent of the input nuclear 
extract is shown in lane 1. B. E2-independent 
interactions between EDD/hHYD and ERs in HeLa nuclear 
extract. M2 agarose-immobilized FLAG-ERa (lanes 5 and 
6) and FLAG-ER(3 (lanes 3 and 4) were incubated with HeLa 
nuclear extracts in the absence (-) or presence (+) of 1 
(iM E2 and bound proteins were eluted with FLAG peptide 
and analyzed by SDS-PAGE and western blot with antibody 
against EDD/hHYD as described in Materials and Methods. 
As a control, HeLa nuclear extract proteins bound to M2 
agarose alone were analyzed in lane 2. One-tenth of input 
nuclear extract was analyzed in lane 1. 
166 
E D D / h H Y D is a n E R interacting nuclear protein 
Input GST GST-ERa GST-ERp 
AB LBD AB LBD 
+ - + - - + E2 (1 uM) 
HYD rn^rnrn %mm mWm% Httl am * 
1 2 3 4 5 6 7 8 
B 
Input M2 f:ERp f:ERa 
+ + - + - E2 (1 |iM) 
* I 
HYD m w 
1 2 3 4 5 6 
against EDD for the GST-pull down assays in Fig.4-1. As 
shown in Fig. 6-1A, EDD/hHYD exhibited interaction with 
GST-ERa AB (lane 3) and E2-dependent interaction with 
GST-ERa LBD (lane 4 versus lane 5) in the nuclear 
extract. In case of ER|3, EDD/hHYD showed no detectable 
interaction with GST-ER(3 AB (lane 6) and E2-enhanced 
interaction with GST-ER(3 LBD (lane 7 versus lane 8) in 
the nuclear extract. To examine these interactions in the 
context of full-length ERs, I carried out western blot 
analysis with antibody against EDD for the eluate from 
the immunoaffnity pull down assay shown in Fig. 4-7. As 
shown in the Fig. 6-1B. EDD/hHYD showed E2-independent 
interaction with ERa (lanes 5 and 6) and ER(3 (lanes 3 and 
4). Interestingly, these results indicated that EDD/hHYD 
interacts with each ER in different manners (see 
discussion). 
The studies described above utilized nuclear extracts 
as a source of EDD/hHYD, did not establish whether other 
factors were essential for these interactions. To further 
investigate this question, I employed the immunoaffinity 
pull down assays as described in chapter 4.2. The binding 
of 35S-labelled full length EDD/hHYD to purified and 
immobilized full length ERa and ER(3 was analyzed. As 
shown in Fig. 6-2A, full length EDD/hHYD showed the E2-
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Fig. 6-2. E2-independent direct interactions between 
isolated EDD/hHYD and full-length ERs. A. Direct 
interactions isolated full length EDD/hHYD and full-
length ERs. M2 agarose immobilized full length ER(3 and 
ERa (lanes 2, 3, 4 and 5) and M2 agarose alone (lane 6) 
were incubated with 35S-labeled (in vitro translated) full 
length EDD/hHYD in the presence (+; lanes 2 and 4) or 
absence (-; lanes 3 and 5) of 1 \iK E2. After washing, 
bound proteins were eluted with FLAG peptide and analyzed 
by autoradiography. Lane 1 shows one-twentieth of the 35S-
labeled full length EDD/hHYD input. B. Direct 
interactions truncated EDD/hHYD and full-length ERa. M2 
agarose immobilized full length ERa (lanes 2, 3, 5 and 6) 
were incubated with 35S-labeled (in vitro translated) 
truncated EDD/hHYD wild type (WT HYD (S)) and mutant (MT 
HYD (S))in the presence (+; lanes 2 and 5) or absence (-; 
lanes 3 and 6) of 1 \xM E2. After washing, bound proteins 
were eluted with FLAG peptide and analyzed by 
autoradiography. Lanes 1 and 4 show one-twentieth of each 
35S-labeled EDD/hHYD input. 
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independent interaction with ERa, as observed with the 
nuclear extract. This indicated the direct interaction of 
EDD/hHYD with ERa. The interaction of the full length 
EDD/hHYD with ER(3, however, was not detectable. This 
might be due to the fact that the expression level of 
full-length EDD/hHYD protein was so low and the 
interaction of EDD/hHYD with ER(3 was weaker than with ERa 
as observed in nuclear extract. Binding of truncated 
EDD/hHYD (1877-2799) to immobilized ERa was analyzed 
because of the following: 1) the difficulty in the 
expression of full length EDD/hHYD; 2) the truncated 
EDD/hHYD (1877-2799) contains a LXXLL motif among five 
LXXLL motifs (at amino acids 248, 1102, 1255, 1398, and 
2428); and 3) the availability of the construct encoding 
the truncated EDD/hHYD (1877-2799). As shown in Fig. 6-2B 
this truncated EDD/hHYD showed E2-independent interaction 
with ERa (lanes 2 and 3) as observed with the full-length 
EDD/hHYD. This result confirms that the isolated EDD/hHYD 
can directly interact with ERa. 
To examine the role of the ubiquitin binding 
activity in the interaction of EDD/hHYD, binding of a 
mutant EDD/hHYD (1877-2799, C2768A) to immobilized ERa 
was analyzed. This mutant EDD/hHYD also showed E2-
independent interaction with ERa (lanes 5 and 6) as 
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observed with the corresponding wild-type fragment. This 
indicated that the ubiquitin binding activity of EDD/hHYD 
is not required for the direct interaction between the 
isolated fragment of EDD/hHYD and ERa. 
6.1.2. Effect of HYD on ER-mediated transcription 
To examine role of EDD/hHYD in ER-mediated 
transcripton, I employed transient transfection assays. 
CV1 cell line is a simian kidney cell line which does not 
express ER and used commonly for the transient 
transfection assays with ER. CV1 cells were transfected 
with the indicated amounts of the plamids harboring ERa 
and EDD/hHYD, in combination with a reporter plasmid 
containing three ERE and core promoter, in the presence 
(E2) or the absence of E2 (No E2). 
In this assay (Fig. 6-3), a strong E2 response (up to 30-
fold induction at the 1 ng of ERa) was observed and this 
was further enhanced upon simultaneous transfection of 
the plasmids encoding full length EDD/hHYD. Due to the 
repressive effect by EDD/hHYD (1.4-fold at the 
concentration of 125 ng and 2.7-fold at the concentration 
of 250 ng of plasmids for EDD/hHYD) the net induction of 
E2 response was enhanced up to 6-fold by EDD/hHYD. This 
result was very reproducible, however, it was not 
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Fig. 6-3. Role of EDD/hHYD in ERa-dependent transcription 
in CVl cells. CVl cells were transfected with indicated 
amounts of expression vectors for ERa and EDD/hHYD in 
combinations with 3ERE-luciferase reporter and control 
luciferase pRL-CMV as described in Materials and Methods. 
Cells were cultured in the absence (-) or presence (+) of 
the ligand, E2 (IO"8 M) , and dual luciferase activities 
were measured 36 hr after transfection. Values (means ± 
SD of a representative experiment performed in duplicate) 
are plotted as a fold. 
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possible to confirm the expression of exogenous EDD/hHYD 
probably due to the limited sensitivity of the antibody 
against EDD/hHYD. Considering the observation of E2-
independent interaction of EDD/hHYD with ERa, this 
indicated that EDD/hHYD could be a potential cofactor for 
ERa through its dual role by acting as a corepressor in 
the absence of E2 and as a coactivator in the presence of 
E2. 
To extend this analysis with more physiologically 
relevant conditions, an Ishikawa cell line was employed. 
Ishikawa cells were transfected with indicated amounts of 
plasmids encoding full length EDD/hHYD in combinations 
with each reporter plasmid containing three ERE sites 
(Fig. 6-4A) or an AP-1 site (Fig. 6-4B) or core promoter 
only (Fig. 6-4C). 
As shown in Fig. 6-4A, a very strong E2 response (up 
to 100-fold) by endogenous ERs was observed with a 
synthetic reporter containing three ERE sites. In 
contrast to what was observed with CVl cells, E2 response 
was moderately enhanced (1.5 fold) at the lowest 
concentration (10 ng of plasmid) of EDD/hHYD and then 
attenuated (up to 1.5 fold) upon increasing concentration 
of EDD/hHYD essentially in a dose dependent manner 
although the level of ER-mediated transcription was not 
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Fig. 6-4. Role of EDD/hHYD in ER dependent transcription 
in Ishikawa cells. Ishikawa cells were transfected with 
indicated amounts of expression vectors for EDD/hHYD in 
combinations with luciferase reporter containing 3ERE 
(A), AP-1 (B) and no activator binding site (C) and 
control luciferase pRL-CMV as described in Materials and 
Methods. Cells were cultured in the absence (-) or 
presence ( + ) of the ligand, E2 (IO"8 M) , and dual 
luciferase activities were measured 36 hr after 
transfection. Values (means ± SD of a representative 
experiment performed in duplicate) are plotted as a fold. 
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vector HYD10 HYD50 HYD100 HYD250 
affected by EDD/hHYD in the absence of ligand or in the 
presence of tamoxifen. This modest effect by exogenous 
EDD/hHYD might be due to the effect by endogenous 
EDD/hHYD in Ishikawa cells and the artificial effect by 
the multiple sites of ERE which might bypass the 
requirement for cofactors. 
A reporter containing one AP-1 site was employed to 
address the second possibility as well as to examine 
promoter specificity of the role of EDD/hHYD, if any. As 
shown in Fig. 6-2B, a weaker E2 response (up to 7-fold) 
from the AP-1 site than from three ERE sites was 
observed. As described previously, Ishikawa cells 
exhibited a strong tamoxifen response (up to 7-fold) from 
the AP-1 site. Although the absolute level of 
transcription activity from AP-1 site in the presence of 
either E2 or tamoxifen appeared to be attenuated by 4-
fold at the highest concentration of EDD/hHYD the net 
induction was not affected by EDD/hHYD due to the 
attenuation of the transcription activity from AP-1 site 
in the absence of ligand. The basal activity from a 
control reporter containing only core promoter (Fig. 6-
4C) was not affected at the highest concentration of 
EDD/hHYD in the presence or the absence of E2. This 
indicated that the reduction in the level of activity 
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from the AP-1 site could be mainly due to the reduction 






ER mediates estrogen signaling through regulation of gene 
expression via direct and/or indirect ways by a variety 
of mechanisms as described above. Considering the broad 
functions of estrogen, the existence of only two ERs may 
require such diversity and complexity of ER action 
mechanisms. Cofactors are considered as ultimate 
integrators and processors of these various mechanisms. 
The diversity of cofactors provides (1) the interfaces to 
accommodate various regulatory information imparted by 
enhanceosomes, chromatin structure, and general 
transcription machinery; (2) the means to integrate 
secondary signaling pathways with estrogen signaling via 
cross-talk; and (3) mechanisms, through cofactor 
modulation, to dictate the specificity of ER function 
depending on the different cell types, promoters and 
ligands. Therefore, understanding the cofactors that 
regulate ER function is particularly interesting, and 
important. 
With respect to this notion, I initially proposed 
the existence of more novel cofactors involved in ER 
function, on the basis of the existence of receptor 
subtypes (a and (3) with different tissue distributions, 
functions and ligand responses; cell and promoter 
context-dependent functions of resident (AF-1 and AF-2) 
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activation domains; and the existence of selective 
estrogen receptor modulators (reviewed in McDonnell, 
1999). 
The object of this thesis work was to identify the 
ER-interacting proteins (presumptive cofactors) that are 
involved in specificity of subtypes of ER and/or cell 
types. Here I described the purification and partial 
characterization of ER LBD-interacting proteins in an E2-
dependent manner. 
7.1. Cell type specificity of ER-interacting proteins 
The apparent lack of major differences in the 
electrophorectic migration patterns of the polypeptides 
interacting with GST-ERa LBD and GST-ER(3 full-length in 
the cell types that I used was quite surprising. However, 
cell type specific functions of ERs might be mediated 
through proteins that weakly interact with ER LBDs and/or 
a repertoire of cell type-specific proteins that interact 
with the AF-1 domains of ERs although I have not pursued 
in sufficient depth to ascertain. Therefore, the initial 
hypothesis could be still valid. In support of this idea, 
the recent study showed the difference in the expression 
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level of SRC-1 between MCF-7 and Ishikawa cells 
contributes the difference in cell type-specific ER 
function in these cell lines (Shang et al., 2000). 
7.2. Subtype Specificity of ER functions 
Although previous studies have reported activation 
by ERa in cell free systems (Kraus and Kadonaga, 1998; Wu 
et al., 1999), this is the first report to compare the 
intrinsic activities of ERa and ER(3 in a fully-defined 
system reconstituted with essentially homogeneous 
factors. Our observation that ER(3 is more potent than ERa 
in the TRAP/Mediator-dependent assay system is somewhat 
surprising in view of reports that ERa is generally more 
active than ER(3 in transfection assays with ectopic 
reporters (reviewed in Hall and McDonnell, 1999; Nilsson 
et al., 2001; Pettersson and Gustafsson, 2001). 
However, the in vitro transcription data correlate 
directly with my observation that intact ER(3 has a higher 
affinity for TRAP/Mediator than does intact ERa. 
Furthermore, promoter and cell context-dependent effects 
of ER AF-1 and AF-2 domain are well established (reviewed 
in Hall and McDonnell, 1999; Nilsson et al., 2001; 
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Pettersson and Gustafsson, 2001). Especially relevant to 
the present findings, an ER(3 lacking the AB domain is 
much more active than an ERa lacking the AB domain in 
certain (e.g. HeLa) cell types (Hall and McDonnell, 
1999). This reflects the well established synergy of 
ERa AF-1 and AF-2 domains (Hall and McDonnell, 1999; 
Nilsson et al., 2001; Pettersson and Gustafsson, 2001) 
and an apparent inhibitory effect of ER(3 AF-1 on ER(3 AF-2 
function (Hall and McDonnell, 1999). Since ERa AF-1 
function has been shown to involve site-specific 
phosphorylation and recruitment of cofactors not present 
in our in vitro assay (Watanabe et al., 2001 and 
references therein) my results likely reflect an 
intrinsic AF-2 function mediated through TRAP/Mediator 
interactions. 
In contrast to this thesis study, but consistent 
with the cell-based studies, a recent report showed that 
ERa is more potent than ER(3 in an in vitro transcription 
assay with chromatin template but not with a naked DNA 
template (Cheung et al., 2003). Cheung et al also 
demonstrated that A/B region of ERa but not ER(3 contained 
potent transcriptional activity with chromatin template 
based assays not with naked DNA based assays (Cheung et 
al., 2003). Thus, it was suggested that the stronger 
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activity of ERa than that of ER|3 shown in their study 
could be mainly due to the stronger AF-1 activity of ERa 
than that of ER(3 (Cheung et al. , 2003). Considering the 
fact that Cheung et al employed the extract-based systems 
for both chromatin assembly and transcription assays, the 
difference in the transcriptional activity of ERa and ER(3 
observed in their study could be significantly mediated 
via additional factors, which present in the extract that 
support ERa AF-1 activity at the step of antirepression 
of the chromatin, rather than the intrinsic 
transcriptional attributes (ER(3>ERa) mediated via GTFs 
(TFIIB, TFIID, TFIIE, TFIIH, polll, and PC4) and 
TRAP/Mediator as seen in this thesis study. Also of 
importance is my observation that the differential 
affinities of TRAP/Mediator for intact ERs (|3>a) are 
reversed when the AB domains are absent (a>(3). This 
clearly indicates an ability of the AB domains to 
modulate interactions of the LBD (AF-2) domains with 
TRAP/Mediator (and probably other cofactors), although it 
is not clear whether this reflects an inhibitory effect 
of the ERa AB domain on ERa AF-2 interactions and/or a 
stimulatory effect of the ER(3 AB domain on ER(3 AF-2 
interactions with TRAP/Mediator. A very recent report on 
an inhibitory activity of part of the ERa AB domain 
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strongly supports the first possibility (Metivier et al., 
2002). Additionally, the results reported here likely 
reflect intrinsic (intramolecular) effects of the AB 
domain(s), rather than effects of additional AB domain-
interacting factors, since similar effects were observed 
with unpurified (nuclear extract) and highly purified 
TRAP/Mediator. Although both Freedman and colleagues 
(Burakov et al., 2000) as well as I failed to see 
differential interactions of ERa and ER(3 with isolated 
TRAP220, Treuter and colleagues (Warnmark et al., 2001) 
have reported stronger interactions of isolated TRAP220 
(and TRAP22 0 fragments) with ER(3 than with ERa. Although 
the basis for these discrepancies is not clear, the 
latter results are consistent with our observation of 
stronger ER(3 interactions with TRAP2 2 0 in the more 
physiological context of the functional TRAP/Mediator 
complex. Given that other AF-2-interacting coactivators 
such as pl60/SRC members show little subtype selectivity 
in ER binding (Burakov et al., 2000; Warnmark et al., 
2001) and as discussed by Warnmark et al. (Warnmark et 
al., 2001), the differential binding of TRAP/Mediator to 
ERa and ER(3 has significant implications for differential 
functions of these receptors in diverse tissues that 
could show modulations of TRAP/Mediator components. The 
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differential recruitment of these factors may also 
contribute to the tissue-selective action of selective ER 
modulators. Finally, apart from a number of other 
interacting factors (reviewed in Nilsson et al., 2001) 
implicated in ER functions, it will be important to 
further characterize the additional ER-interacting 
polypeptides identified here (Fig. 3-2) for possible 
subtype-specific functions and interactions with 
TRAP/Mediator, other cofactors, and the general 
transcription machinery. 
7.3. TRAP/Mediator is a Bona Fide Estrogen Receptor 
Coactivator 
Following earlier reports of ligand-dependent 
interactions of ERs with the isolated TRAP220 subunit of 
the multicomponent (circa 25 subunit) TRAP/Mediator 
complex (Burakov et al., 2 000; Warnmark et al., 2 001; 
Yuan et al., 1998; Zhu et al., 1999), this thesis study 
provides concrete evidence for direct TRAP2 2 0- and 
ligand-dependent interactions of ERs with the intact 
TRAP/Mediator complex and a direct role for the complex 
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in ER function through the general transcription 
machinery. 
While a role for the complete TRAP/Mediator in ER 
function had been inferred from TRAP220 binding studies 
(Burakov et al., 2000; Warnmark et al., 2 001; Yuan et 
al., 1998; Zhu et al., 1999), and from the precedents 
established with TR and VDR (Fondell et al., 1996; Rachez 
et al., 1998), the concurrent failures (see above) to 
show any interactions of the intact TRAP/Mediator complex 
with ERs had led others to speculate that class I 
(steroid hormone) nuclear receptors might utilize 
different cofactors from TRAP/Mediator (Burakov et al., 
2000). This thesis work provides the first evidence for 
the involvement of the intact TRAP/Mediator complex in 
the function of class I (steroid hormone) nuclear 
receptors. 
Consistent with the earlier results, and with 
structural conservation of the AF-2 domain implicated in 
ligand-dependent interactions of many cofactors, this 
thesis work shows ligand-dependent interactions of 
TRAP/Mediator both in nuclear extracts and in purified 
form with both ERa and ER(3 LBDs. The latter results 
establish that these interactions are direct, while 
analyses with extracts from TRAP220"/_ fibroblasts 
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establish an essential role for TRAP220 in these 
interactions. Consistent with their role in TR and VDR 
interactions, the TRAP220 LXXLL motifs (most notably NR 
box 1) have been implicated in ligand-dependent ERa and 
ER|3 interactions with isolated TRAP220 (Burakov et al., 
2000; Warnmark et al., 2001). Thus, although reported 
ligand-independent interactions of ERs with other 
isolated TRAPs (Burakov et al., 2000) could be relevant, 
they are insufficient for demonstrable interactions of 
the entire TRAP complex with ERs. Related, I did not 
observe any direct interactions of TRAP/Mediator with ER 
N-terminal AB domains. 
Importantly, the physiological relevance of the in 
vitro interactions is substantiated by our demonstration 
of an in vivo association of the entire TRAP/Mediator 
complex with an ERa derivative lacking the AB domain. 
Along with the in vitro data, this observation makes 
improbable the suggestion (Burakov et al., 2000) that 
TRAP22 0 may mediate ER function independently of many or 
all of the other TRAP/Mediator subunits. In a further 
analysis of the significance of TRAP/Mediator 
interactions, and perhaps most importantly, this thesis 
work demonstrates that the purified TRAP/Mediator complex 
markedly enhances ER function on DNA templates both in 
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nuclear extracts and in a system reconstituted with 
highly purified factors. This firmly establishes a direct 
function for TRAP/Mediator in mediating the action of ERs 
on target promoters in conjunction with the general 
transcription machinery. 
A recent report utilizing in vitro transcription 
assays with a chromatin template showed only a modest 
effect (1.3 to 2 fold on activated transcription by ERa) 
on ER-dependent transcription upon TRAP/Mediator 
depletion (Acevedo and Kraus, 2003). This result is 
contrast to my results, which showed the significant 
effect (4 to 7 fold) by TRAP/Mediator on the activated 
transcription by ERs or GAL4-ER LBDs. The difference 
between my study and the study by Acevedo and Kraus might 
be due to different depletion procedures such as using 
different antibodies. Another possibility for the 
different results between my study and their study could 
be difference in templates (naked DNA in my study versus 
chromatin template in their study) although this is quite 
unlikely considering an earlier study showing the 
significant effect on HNF-4 dependent transcription upon 
TRAP/Mediator depletion in nuclear extract-based in vitro 
transcription assays with both DNA and chromatin 
templates (Malik et al., 2002). Most of all, the 
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interpretation of the study by Acevedo and Kraus is 
difficult due to the the lack of restoration experiment 
by adding exogenous TRAP/Mediator complex and possible 
complement by Drosophila Mediator existing in S-190 
extracts. 
7.4. TRAP220 is an essential anchor for ER-TRAP/Mediator 
interaction 
Although a number of previous studies suggested the 
potential involvement of the TRAP220 subunit in ER 
function (Burakov et al., 2000; Warnmark et al., 2001; 
Shang et al., 2000; Zhu et al., 1999; Yuan et al., 1998), 
these studies employed only isolated TRAP220 or fragment 
of TRAP220. Thus, these studies were not able to score 
the function of TRAP220 in the context of intact 
TRAP/Mediator. To address this issue, TRAP220-/- MEFs 
were utilized to examine the roles for TRAP220 in the 
interaction and function of TRAP/Mediator in ER-driven 
transcription. This study was based on the previous 
observation that the residual Mediator subunits can form 
a functional complex for certain activators such as GAL4-
VP16 (unpublished observation by Chao-Xing Yuan). As 
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mentioned above, the loss of TRAP220 abolished the ER-
TRAP/Mediator interaction in nuclear extract indicating a 
role for TRAP220 as an essential anchor for the strong 
TRAP/Mediator-ER interaction. However, and surprisingly, 
transient transfection assays with TRAP220-/- MEFs 
revealed that ER-driven transactivation was reduced only 
modestly (2 fold) by deletion of TRAP220, in contrast to 
what was observed with TR. This was unexpected 
considering the significant effect on ER-TRAP/Mediator 
interaction by deletion of TRAP220. This discrepancy 
might be due to the existence of redundant mechanisms 
that likely compensate for potential defects in ER 
function by the loss of TRAP220 in MEFs. This could be 1) 
the presence of redundant cofactors that play similar 
roles as TRAP220 in MEFs and/or 2) the absence of natural 
constraints (such as a natural chromatin structure) that 
particularly impose a requirement for TRAP22 0 to overcome 
and/or 3) physiologically irrelevant cellular environment 
for ER function given that MEFs do not express ERs and/or 
4) non-physiological template containing multiple ERE 
sites. 
A consideration of studies with PPARy, another 
receptor that shows ligand-dependent interaction with 
TRAP220, exemplified this point. Thus, transient 
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transfection assays with MEFs failed to show a 
significant defect in PPARy-driven transcription in the 
absence of TRAP220 (unpublished observation by Chao-Xing 
Yuan), however, adipogenesis differentiation assay 
revealed the absolute requirement of TRAP220 for PPARy-
induced adipogenesis differentiation and for endogenous 
PPARy target gene expression (Ge et al., 2002). Moreover, 
the GST pull-down assays with TRAP220-/- nuclear extracts 
showed that TRAP220 is an essential for strong 
interactions of PPARywith the TRAP/Mediator, as observed 
for ER. These results strongly support the above 
possibilities and necessitate more physiological cell-
based assays that employ cells in where ER normally 
function in the expression of natural target genes. 
Based on previous studies in assaying the function 
of TRAP/Mediator in ER dependent transcription, I 
employed cell-free assays, as an alternative approaches, 
to assess the role of TRAP220 in ER-dependent 
transcription, particularly in the context of intact 
TRAP/Mediator. However, TRAP/Mediator complex lacking 
TRAP2 2 0 showed no defect in ER-dependent transcription in 
this particular assay- This unexpected observation, 
together with the observation of the requirement of 
TRAP220 for the ER-TRAP/Mediator interaction, led to the 
193 
speculation that 1) whereas TRAP220 play a pivotal role 
in mediating ER-TRAP/Mediator interaction, this may not 
be essential for TRAP/Mediator to support ER dependent 
transcription at the naked DNA template in vitro and 2) 
factors other than ER may be able to recruit 
TRAP/Mediator lacking TRAP220 to the promoter through 
other subunits under the ambient conditions in cell-free 
transcription assays. The dispensability of TRAP220 for 
TRAP/Mediator function in activated transcription in 
cell-free transcription assays has been suggested by 
previous studies in cell free systems showing 1) that 
TRAP/Mediator lacking TRAP220 can support activated 
transcription by certain activators such as GAL4-VP16 and 
HNF-4 (unpublished observation by Sohail Malik) and 2) 
that a preparation of PC2 containing no detectable levels 
of TRAP240, 230, 220, can support activated transcription 
by GAL4-VP16, GAL4-AH and HNF-4 as well as intact 
TRAP/Mediator (Malik et al., 2000). Moreover, and 
importantly, The possibile existence of other factors 
(not activator) that can recruit the residual (TRAP220-
deficient) TRAP/Mediator to the promoter through other 
subunits of TRAP/Mediator was indirectly suggested by the 
previous studies showing an obligate role of the 
TRAP/Mediator in supporting basal (activator-independent) 
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transcription in depleted extracts (Baek et al., 2002; 
Mittler et al., 2001). More direct evidence for this was 
provided by a subsequent study showing that TRAP/Mediator 
was recruited to the promoter in the absence of the 
activator HNF-4 (Malik et al., 2002). 
In addition to the basal effect, TRAP/Mediator also 
supports ER-activated transcription. The question then 
arises as to how TRAP/Mediator supports ER-activated 
transcription. One possible answer to this question is 
that although ER might not be able to directly recruit 
TRAP/Mediator due to lack of TRAP220, residual 
TRAP/Mediator lacking TRAP220 could function in ER-
activated transcription via indirect recruitment through 
other factors. 
Thus, the failure to show a role of TRAP220 in the 
function of TRAP/Mediator to support ER-dependent 
transcription using cell-free assays might be due to an 
intrinsic limitation of cell-free assays. Therefore, it 
will be important to develop assays that impose more 
physiological conditions before taking the conclusions 
regaring the roles for TRAP220 in the function of 
TRAP/Mediator to support ER-dependent transcription. 
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7.5. Role for TRAP220 NR boxes 
The LXXLL motif was first identified as a signature 
sequence motif, in other nuclear receptor coactivators, 
that is necessary and sufficient for direct interactions 
with NRs (Heery et al., 1997). This motif has been found 
in most NR cofactors (Heery et al., 1997). Furthermore, 
this motif functions as a specificity determinant for 
interactions between NRs and cofactors (Mclnerney et al., 
1998). For example, consistent with this notion, it was 
indicated by others that the second (C-terminal) LXXLL 
motif (NR box2) of TRAP2 2 0/DRIP2 05 showed the interaction 
with TR (Yuan et al., 1998) and VDR (Rachez et al., 
1998), whereas the the first motif (more N-terminal) 
LXXLL motif (NR boxl) showed a preferred interaction with 
ERs (Burakov et al., 2 000; Warnmark et al., 2 001). 
However, in contrast to these previous reports, this 
thesis study revealed that ER LBDs prefer TRAP220 NR box2 
to NR boxl in the isolated TRAP220 AB. The difference may 
be due to the different assay condition. Interestingly, 
full-length ER(3 did not show any preference in the 
context of intact TRAP/Mediator and both NR boxes were 
found to be necessary and sufficient for strong ER-
TRAP/Mediator interaction. This, together with previous 
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reports, indicated that each NR box is sufficient for ER-
TRAP220 interaction but not sufficient for efficient ER-
TRAP/Mediator interaction. This suggested cooperative 
action of two NR boxes in ER-TRAP/Mediator interaction. 
In consistent with these results, transient 
transfection assays with MEFs revealed that exogenous 
expression of full-length TRAP220 harboring mutations in 
either or both NR boxes failed to restore the defect in 
ER-driven transcription. The cell-free assays both with 
crude nuclear extract and with purified factors showed 
that TRAP/Mediator complex containing TRAP2 2 0AB NR 
mutants exhibited only very modest defects (1.5 to 2 
fold) in ER-dependent transcription. This is quite 
surprising, considering previous observation of more 
significant effects of the same TRAP220AB NR mutants on 
the activated-transcription by other nuclear receptors 
such as TR (unpublished observation by Sohail Malik and 
Mohamed Guermah) or PPARy (unpublished observation by 
Mohamed Guermah) in cell-free transcription assays. 
These modest effects of TRAP/Mediator containing 
TRAP220AB NR mutants could be due to the same reasons for 
the results of many analyses with TRAP/Mediator lacking 
TRAP220, as addressed in the previous section (chapter 6-
4), provided that mutations of either or both NR boxes of 
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TRAP220 are functionally equivalent to complete loss of 
TRAP220. However, and more importantly, this functional 
outcome could be due to the residual interactions between 
ER and TRAP/Mediator containing TRAP2 2 0AB harboring 
mutations in either or both NR boxes. These weak but 
significant interactions of TRAP/Mediator containing 
TRAP22 0AB NR mutants with ERs could be enough for 
function. In support of this idea, the TRAP220 NR boxes 
are dispensible for the physiological function of PPARy 
which absolutely requires TRAP220 (unpublished 
observation of Kai Ge). 
7.6. Identification of EDD/hHYD as an ER-interacting 
protein 
The previous studies on the EDD/hHYD summarized in 
the chapter 6, pointed out strong relevane of EDD/hHYD in 
ER function. This thesis work provided evident to support 
this possibility although the data presented here is yet 
preliminary-
EDD/hHYD interacts with each ER in subtype-dependent 
manners. EDD/hHYD interacts with GST-ERa AB but not with 
GST-ER(3 AB. This suggested the possible role of EDD/hHYD 
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in the AF-1 activity of ERa. The isolated ERa LBD showed 
E2-dependent interaction with EDD/hHYD, whereas the 
isolated ER|3 LBD showed E2-enhanced interaction. The 
reason for the less E2-dependency of the interaction of 
EDD/hHYD with ER(3 LBD than with ERa LBD has yet to be 
known. It could be due to potential involvement of other 
factors in nuclear extract in the interaction of EDD/hHYD 
with each ER LBD and/or intrinsic properties of ER LBDs 
such as structural difference of each ER LBD. Although it 
needs to be established the difference in E2-dependency 
of the interaction between EDD/hHYD and each ER LBD 
suggested the potential involvement of EDD/hHYD in the 
subtype-specific response of ER to different ligands. In 
contrast to what was observed with TRAP/Mediator, 
EDD/hHYD interacts with full length ERa much stronger 
than with full length ERp, as observed with ER LBDs 
although to somewhat lesser extent. The reason for the 
stronger interaction of EDD/hHYD with full length ERa 
compared to full length ER(3 has yet to be known. However, 
it appeared to be same with the isolated EDD/hHYD this 
might reflect the intrinsic difference in ERa and ER(3 
rather than the other factors in the nuclear extract. 
Interestingly, EDD/hHYD interacts with full length 
ERs in E2-independent manners. The reason for the loss of 
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E2-dependency has yet to be known, however, these resuts 
indicated the modulatory effect of AB regions of ERs, via 
the intrinsic properties of AB regions of ERs, on the 
interaction of EDD/hHYD with corresponding LBDs, as 
suggested from the studies with TRAP/Mediator. 
To examine the potential role of EDD/hHYD as a 
cofactor for ERs, the transient transfection assays with 
two different cell types were carried out. In CVl cells, 
the transfection of exogenous EDD/hHYD resulted in the 
apparent net induction of ERa-mediated transcription 
through its dual action by stimulating E2-dependent 
activity of ER and repressing E2-independent activity. In 
contrast to this, Ishikawa cells exhibited the reduction 
in the activity from the multiple ERE sites as well as 
single AP-1 site upon the transfection of exogenous 
EDD/hHYD in a ligand-independent manner. The discrepancy 
in the results with two cell lines could be due to the 
intrinsic properties of these cell lines, particularly 
the level of endogenous EDD/hHYD protein as well as ERs. 
For example, if Ishikawa cells overexpress endogenous 
EDD/hHYD one might not be able to see the effect of 
exogenous protein. A report that was published during 
this thesis work provided evidence that EDD functions as 
a coactivator for PR and VDR but not for ER (Henderson et 
200 
al., 2002). Henderson et al also reported that neither 
the ubiquitin binding domain nor the E3 ligase activity 
was required for such cofactor function (Henderson et 
al., 2002). 
7.7. Identification of ERLBD-interacting proteins 
independent of TRAP/Mediator 
As detailed in Fig. 3-3, circa 12 polypeptides were 
identified as ERLBD-interacting proteins (ERLIPs). 
Although the functional relevance of their interactions 
with ERa LBD remains to be established there is some 
evidence suggesting their potential involvement in ER 
functions. 
1) DNA-dependent Protein Kinase (DNA-PK) 
The largest protein among the ERLIPs was identified 
as the 450 kDa DNA-PK catalytic subunit. The possible 
role for this protein in modulation of ER function was 
first suggested by an early report showing its ability to 
phosphorylate ERa in vitro (Arnold et al., 1995). 
Additional evidence for the potential link between DNA-PK 
and NR function came from the studies showing an 
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interaction of DNA-PK with certain cofactors such as TRBP 
and GCN5 (Ko et al., 2000). TRBP interacts with CBP/p300 
and DRIP130/hSUR2, a component of the TRAP/Mediator and 
activates transcription by TR and ER (Ko et al., 2000). 
This study also demonstrated DNA-independent 
phosphorylation of TRBP by DNA-PK, although its 
functional relevance was not shown (Ko et al., 2000). 
Furhtermore, phosphorylation of GCN5 by DNA-PK was found 
to down regulate the HAT activity of GCN5, resulting in 
an inhibitory effect on transcription. 
Based on these results, one can propose two possible 
mechanisms by which DNA-PK modulate ER functions: 1) 
direct roles for DNA-PK in modulation of ER activity 
through its phosphorylation of ERa and 2) the indirect 
roles via interactions with other cofactors by 
facilitating recruitment and/or modulating cofactor 
activity through its kinase activity. 
2) Transformation/transcription domain-associated 
protein (TRRAP) 
The second largest protein in ERLIPs was identified as 
the TRRAP component of GCN5/PCAF complexes (Vassilev et 
al., 1998). This is consistent with the previously 
documented E2-dependent recruitment of PCAF to ER-
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regulated target genes (Shang et al., 2000). 
Additionally, there is a report suggesting the 
involvement of TFTC, one of GCN5/PCAF complexes, in ERa 
dependent transcription through direct interaction of 
TRRAP with ERa (Yanagisawa et al., 2002). This study also 
provided evidence that TRRAP is involved in E2-dependent 
cell growth of breast cancer cells. However, the data 
from in vitro transcription assays were not so convincing 
because this study failed to demonstrate the activity by 
TFTC complex by itself and the effect on cell growth by 
antisense TRRAP could be a secondary effect. 
3) RNA Polymerase II subunit 
Although the direct interaction of RNA pol II with ER 
has not been indicated heretofore, RNA pol II has been 
shown to be associated with TRAP/Mediator in certain 
cases. Therefore, it is highly possible that RPB2 might 
indirectly interact with ER LBD via TRAP/Mediator. 
4) Striatin, S/G2 Nuclear autoantigen (SG2NA), Zinedin, 
Protein phosphatase 2A (PP2A) and hMOBl/Phoecin 
These proteins were shown to form a PP2A holoenzyme 
complex with calcium-independent, okadaic acid-sensitive 
phosphatase activity (Baillat et al., 2001; Moreno et 
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al., 2001; Moreno et al., 2000). These studies suggested 
that Striatin, S/G2 Nuclear autoantigen (SG2NA), Zinedin, 
and hMOBl/Phoecin form a novel B subunit of PP2A 
holoenzyme. 
PP2A is a heterotrimeric serine/threonine phosphatase 
consisting of structural (A) subunit, catalytic(C) 
subunit and regulatory (B) subunit. Existence of several 
types of B subunits-B, B', B", B'" could produce many 
different holoenzyme assemblies which can modify specific 
substrates in distinct cellular environment. This 
structural diversity and complexity of PP2A could create 
the multifunctional nature of PP2A that is involved in 
cellular metabolism, neuronal signaling, development, 
cell cycle regulation and viral transformation. 
Striatin, SG2NA and Zinedin have been shown to be a 
striatin family due to their high homology. These 
proteins contain multiple protein-protein interacting 
domains including a caveolin-binding domain, potential 
coiled-coil structure, a calmodulin-binding domain, a 
membrane-binding domain and a WD-repeat domain (Castets 
et al., 2000). With respect to these structural features 
these proteins have been thought to function as 
scaffolding proteins by assembling a large number of 
proteins into a complex (Castets et al., 2000). Thus, 
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these proteins target other proteins to certain cellular 
compartments. Additionally, their binding ability to 
calmodulin in the presence of calcium suggesting their 
function in or depending on calcium signaling (Bartoli et 
al., 1998) (Castets et al., 2000). Another interesting 
feature of these proteins is that they expressed 
primarily in the central nervous system suggesting their 
function in the brain. 
Among those, SG2NA was originally isolated as an 
autoantigen in a human cancer patient (Muro et al., 1995) 
and localized to the nucleus although it is primarily 
localized to the cytosol and the membrane. As its name 
indicated its expression peaks during the S and G2 
suggesting its involvement in cell cycle (Muro et al., 
1995) . 
Striatin was found in neurons of mammalian basal 
ganglia and cranial and spinal motor nuclei specifically, 
neuronal dendrites (Castets et al., 1996; Moqrich et al., 
1998; Salin et al., 1998). Different from SG2NA, striatin 
was found in the cytosol and in membranes (Castets et 
al., 1996) and contains two polybasic domains that are 
absent in SG2NA and may facilitate association with the 
post-synaptic membrane (Castets et al., 1996). Its 
physiological function was further supported by the 
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observation that downregulation of striatin in vivo using 
antisense oligonucleotides decreased locomotor activity 
and reduced growth of dendrites in vitro (Bartoli et al., 
1999). These results suggested that striatin with the 
PP2A A/C heterodimer target to a cellular 
microenvironment in which it may play a role in the 
modulation of calcium-dependent neuronal signaling and 
possibly remodeling of the cytoskeleton. 
There are a couple of reports suggesting the 
involvement of these proteins in regulation of 
transcription. An early report provided evidence that 
PP2A catalytic subunit can potentiate transcription from 
the AP-1 sites (Alberts et al., 1993). SG2NA was 
suggested to contain transcriptional activity (Zhu et 
al., 2001). Although their involvement in estrogen 
signaling has not yet been clearly demonstrated there is 
a report showing that direct interaction of PP2A 
catalytic subunit with ERa and increase in ER-driven 
transcription upon treatment of okadaic acid via inducing 
ER-MAPK interaction (Lu et al., 2003). However, it is 
more likely that PP2A might involve in ER-driven 
transactivation rather than inhibition based on the 
observation of the ligand-dependent interaction of PP2A 
with ERa. Moreover, the interpretation of the data on ER-
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driven transactivation with okadaic acid is difficult 
based on the following: 1) the effect of okadaic acid 
could be secondary effect and 2) one should include 
proper control for the specificity such as by showing 
that other activator dependent transcription is not 
affected. 
5) Calmodulin-dependent kinase II (CaMKII) 
CaMKII, similar to CaMKI, is widely expressed 
throughout the body whereas CaMKIV is relatively 
restricted to the brain, T-lymphocytes and post-meiotic 
male germ cells. Its dual roles in transcription 
regulation have been suggested by a report showing that 
CaMKII phosphorylates ATF-1 at Ser63 and activate its 
transcriptional activity by enhancing the interaction 
with CBP while it phosphorylates CREB at Serl42 and 
inhibit its transcriptional activity by reversing the 
activation of CREB by destabilizing the association 
between CREB and CBP (Shimomura et al., 1996). Similar 
to PP2A this kinase may be more relevant to the 
nongenomic actions of ER rather than genomic actions. 
However, this possibility remains to be investigated. 
207 
7.8. Perspectives 
Estrogen involves diverse physiological processes in 
various tissues. Thus, natural estrogen withdrawl in 
women in the postmenopausal period has caused 
pathological symptoms called postmenopausal syndrome. 
Particularly, today the increasing life span has 
generated increasing population of women in the 
postmenopause stage and longer postmenopausal period of 
their lives meaning that more women would suffer from 
postmenopausal syndrome for longer period. Estrogen also 
has known to be involved in the carcinogenesis of breast 
and uterine. Therefore, estrogen has been getting 
considerable clinical and pharmaceutical attention due to 
its significance in women's health. In particular, it is 
of great interest to develop new SERMs as substituents 
for hormone replacement therapy that retain the 
beneficial effects of estrogen, but lack of higher risk 
of breast cancer or uterine cancer. Understanding the 
molecular mechanism of estrogen action and its receptor 
ER can eventually be foundation for the discovery of 
proper SERMs to treat or prevent estrogen-related 
diseases. 
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A prerequisite for understanding the molecular 
events underlying the ER-mediated estrogen action is the 
identification of all the players involved. In this 
respect I believe that my thesis work has contributed to 
scientific progress by identifying and partially 
characterizing some of the ER-interacting proteins 
(presumptive cofactors). 
Future studies must elucidate the physiological 
roles for TRAP/Mediator in ER function. As reviewed in 
the previous sections, TRAP/Mediator would link the 
diverse gene-specific transcriptional factors and basal 
transcription machinery and provides accommodating 
surfaces to transcription apparatus with its modular and 
dynamic organization upon diverse regulatory signals. In 
this way, TRAP/Mediator could act ultimately (1) to 
assemble various regulatory signals from enhanceosomes 
into an integrated synergistic response to the basal 
transcription machinery at the promoter of a given gene 
and (2) to coordinate afferent signals from various 
signaling pathways in the context of the cellular 
environment into an incorporated differential response to 
the cell and tissue of a whole organism. In view of the 
first aspect, future studies must be directed towards 
illumination of the molecular mechanisms by which 
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TRAP/Mediator connects ERs and the components of basal 
transcription machinery- In view of the second aspect, it 
will be very important and interesting to study the 
involvement of TRAP/Mediator in various signaling 
pathways involved in differentiation and/or development. 
In other words, the physiological relevance of 
TRAP/Mediator in ER function, as observed in PPARy-
induced adipocyte differentiation should be investigated. 
For example, RNAi with breast cancer cells to see 
potential relevance of amplification of TRAP220 in breast 
cancer. Generation of tissu-specific conditional TRAP220 
knock-out mice would provide more insights of the role of 
TRAP22 0 and TRAP/Mediator complex in the mammalian 
physiology including nuclear receptor function. 
Furthermore, such physiological approaches could assess 
the functional relevance of absolute requirement of 
TRAP2 2 0 in ER-TRAP/Mediator interaction. 
Other future studies will have to characterize the 
function of ER-interacting proteins other than 
TRAP/Mediator in both nongenomic and genomic actions of 
ERs, elucidate the molecular mechanism leading to ER 
function through these proteins, and address questions of 
possible subtype specificities of these proteins. 
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Another question provoked by the existence of 
diverse cofactors for ER function is the functional 
relationship among these proteins whether they function 
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